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A risk analysis of in utero caffeine exposure is presented utilizing epidemiological studies and animal studies dealing with
congenital malformation, pregnancy loss, and weight reduction. These effects are of interest to teratologists, because animal
studies are useful in their evaluation. Many of the epidemiology studies did not evaluate the impact of the ‘‘pregnancy signal,’’
which identifies healthy pregnancies and permits investigators to identify subjects with low pregnancy risks. The spontaneous
abortion epidemiology studies were inconsistent and the majority did not consider the confounding introduced by not
considering the pregnancy signal. The animal studies do not support the concept that caffeine is an abortafacient for the wide
range of human caffeine exposures. Almost all the congenital malformation epidemiology studies were negative. Animal
pharmacokinetic studies indicate that the teratogenic plasma level of caffeine has to reach or exceed 60mg/ml, which is not
attainable from ingesting large amounts of caffeine in foods and beverages. No epidemiological study described the ‘‘caffeine
teratogenic syndrome.’’ Six of the 17 recent epidemiology studies dealing with the risk of caffeine and fetal weight reduction
were negative. Seven of the positive studies had growth reductions that were clinically insignificant and none of the studies
cited the animal literature. Analysis of caffeine’s reproductive toxicity considers reproducibility and plausibility of clinical,
epidemiological, and animal data. Moderate or even high amounts of beverages and foods containing caffeine do not increase
the risks of congenital malformations, miscarriage or growth retardation. Pharmacokinetic studies markedly improve the
ability to perform the risk analyses. Birth Defects Res (Part B) 92:152–187, 2011. r 2011 Wiley-Liss, Inc.
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This Teratogen Update of the reproductive and developmental risks of
caffeine is dedicated to Mildred S. Christian, better known to her friends and
colleagues as Millie. This manuscript is the third publication that Millie and I
will have coauthored. She spent the last year of her life working on this
manuscript with her usual indefatigable perseverance. In a recent published
essay the author quoted his father’s philosophy of life who said, ‘‘The young
may die, but the old have to.’’ Whatever her age, Millie was young. She was
young in spirit, enthusiasm, creativity, and productivity. Millie was a brilliant
toxicologist and had a broad intellectual grasp of science. Because of her
expertise, she was frequently consulted by pharmaceutical and chemical
companies to analyze preclinical studies that needed an objective experienced
toxicologist. She received accolades and praise from the entire teratology and
toxicology community. Dr. Christian completed her doctorate in the
Teratology-Developmental Biology Training Program at the Jefferson Medical
College of Thomas Jefferson University. She was a good graduate student and
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INTRODUCTION AND GOALS
OF THIS REVIEW
We (Brent and Christian) received a request from the
Caffeine Committee of the International Life Science
Institute (ILSI) in 2008 to update our 2001 review since
many publications dealing with the effects of caffeine
had been published (Christian and Brent, 2001).
A current literature review of human epidemiology
studies, animal studies, and caffeine toxicology studies
was performed using the Medline and Toxline data
bases, articles in the author’s files, and publications
containing important relevant information published
earlier than 2001.
Goals of This Review
One of the reasons that epidemiologists have focused
so much attention on the effects of caffeine is that
caffeine is the most widely used CNS stimulant in the
world. At doses achieved in normal human consump-
tion, the main effect mediated by caffeine is interaction
with the adenosine receptor, as well as with adrenergic,
cholinergic, GABA, and serotonin receptors (Shi et al.,
1993; Leon, 2005a,b).
We recognize that well-planned epidemiology studies
are the most useful for performing accurate human risk
assessment. When epidemiological studies are inconsis-
tent, animal studies that utilize exposures that occur in
humans can provide additional information that is
necessary to perform a risk analysis. Animal studies are
most useful if plasma and tissue blood levels of caffeine
and/or caffeine metabolites are measured and can be
compared with human exposures. We planned to use the
same protocol for estimating the human risks of devel-
opmental and reproductive problems that were utilized
in the 2001 caffeine review (Christian and Brent, 2001)
(Table 1). The data reviewed in this manuscript are
divided into three sections: Epidemiology studies,
Animal and in vitro toxicology studies, and Pharmaco-
kinetic studies.
EPIDEMIOLOGY STUDIES
We have reviewed human epidemiology publications
that deal with
A. Pregnancy loss (miscarriage and spontaneous abor-
tion [SAs])
B. Congenital malformations CMs, and
C. Fetal growth retardation (IUGR, SGA).
Although some of the epidemiological studies have
examined more than one developmental effect, many of
the studies have focused on one developmental end-
point. Two of the important studies cited and discussed
in our 2001 caffeine review (Christian and Brent, 2001)
were performed by Klebanoff et al. (1998, 1999). The
reason for their importance is that the exposure to
caffeine was determined pharmacokinetically by mea-
suring serum caffeine and paraxanthine concentrations.
Etiology of SA (Miscarriage and Pregnancy Loss)
Concern about the risk of SA from exposure to caffeine
was one of the reasons for preparing this review. Many of
the epidemiological studies fail to assess the factors that
can alter the accuracy of epidemiological studies dealing
with SA.
Causes of SA. SAs, frequently referred to as
miscarriages by the public, are common occurrences
during pregnancy. According to the World Health
Organization, 15% (with a large standard deviation) of
women who know that they are clinically pregnant
spontaneously abort. Research studies indicate that a
higher percentage of embryos are spontaneously aborted
before the first-missed menstrual period before the
mothers know that they are pregnant (Tables 3 and 4).
The lay population and the news media are under the
impression that many SAs are due to exposures to some
type of toxic agent during the woman’s pregnancy. This
is an erroneous conclusion since most early SAs are due
to chromosome abnormalities that are determined before
conception because of chromosome aberrations that are
Table 1
Evaluating the Allegation of Teratogenicity
Epidemiological Studies: Controlled epidemiological studies consistently demonstrate an increased incidence of a particular spectrum of
embryonic and/or fetal effects in exposed human populations
Secular Trend Data: Secular trends demonstrate a positive relationship between the changing exposures to a common environmental
agent in human populations and the incidence of a particular embryonic and/or fetal effect
Animal Developmental Toxicity Studies: An animal model can be developed, which mimics the human developmental effect at clinically
comparable exposures. Since mimicry may not occur in all animal species, animal models are more likely to be developed once there
is good evidence for the embryotoxic effects reported in the human. Developmental toxicity studies in animals are indicative of a
potential hazard in general rather than the potential for a specific adverse effect on the fetus when there are no human data on which
to base the animal experiments
Dose–Response Relationship: Developmental toxicity in the human increases with dose (exposure) and the developmental toxicity in
animal occurs at a dose that is pharmacokinetically (quantitatively) equivalent to the human exposure
Biological Plausibility: The mechanisms of developmental toxicity are understood and the effects are biologically plausible
(a) Mechanisms
(b) Receptor agonistic or antagonistic studies
(c) Enzyme suppression
(d) Nature of the malformations
(e) Teratology principles
Modified from Brent (1986, 1995a,b).
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inherited, occur during the development of the sperm, or
the mother’s ova (eggs). Some maternal diseases can also
be responsible (Tables 3–5). Fifty to 60% of the early
spontaneously aborted fetuses have chromosomal ab-
normalities (Bernirschke, 1974; Boue et al., 1975; Simp-
son, 1980).It has been estimated that up to 30–40% of all
fertilized ova in the human are lost within the first three
weeks of development (Hertig, 1967). This means that
SAs are a common event and are due to many causes
(Table 3). SAs can result from inherited or acquired
chromosomal abnormalities, inherited diseases, medi-
cally or environmentally produced blighted (malformed)
embryos, maternal illness, lupus anticoagulant factor
(WHO, 1970; Stein et al., 1975; Kline and Stein, 1985;
Beckman and Brent, 1986; Abenhaim and Lert, 1991). A
more complete list of the causes of SAs is in Table 3.
Epidemiological investigations dealing with the causes
of SAs must deal with formidable problems:
(1) A majority of SAs that occur early in pregnancy are
due to chromosomal abnormalities that are unrelated
to environmental exposures during pregnancy
(Tables 2, 4, and 5).
(2) The risk of abortion changes with each day of
pregnancy, so that it is essential to properly match
controls, to eliminate the selection of two populations
with different background SA rates (Table 2).
(3) Attempts to control for the hidden incidence of
medical abortions have only limited success (Susser,
1983; Olsen, 1984). ‘‘The existence of high rates of
medically induced abortion in the population may
distort currently employed measures of the rate of
SAs’’ (Susser, 1983). Susser indicated that women not
infrequently would report medically induced abor-
tions as SAs (‘‘The Susser effect’’).
(4) Reduction of coffee consumption and aversion to
other odors and tastes is one of the earliest responses
of the ‘‘pregnancy signal’’ that occurs in healthy
pregnancies, during the pregnancy stages when
chorionic gonadotropin (HCG) is at a high level.
The ‘‘pregnancy signal’’ tends to separate the healthy
pregnancies from the less healthy ones. Ignoring the
importance of the pregnancy symptoms can seriously
undermine the accuracy of SA and other reproduc-
tive toxicity studies.
SA Articles That Will Be Discussed
Cnattinglus et al. (2000), Zusterzeel et al. (2000)
Signorello et al. (2001), Wen et al. (2001), Klonoff-Cohen
et al. (2002), Giannelli et al. (2003), Rasch (2003), Tolstrup
et al. (2003), Khoury et al. (2004), Sata et al. (2005),
George et al. (2006), Karypidis et al. (2006), Maconochie
et al. (2007), Savitz (2008), Weng et al. (2008), Greenwood
et al. (2010).
In the Cnattinglus et al. (2000) and the Maconochie
et al. (2007) studies there were no increased risks in the
groups exposed to more than 500 mg/day of caffeine.
The Cnattinglus et al. (2000) publication was one of the
few caffeine studies to consider the fetal karyotype. These
authors also obtained information concerning nausea and
vomiting symptoms; however, these data were insuffi-
cient to evaluate the pregnancy signal. In some of the
studies there was no control for the presence or absence of
the ‘‘pregnancy signal.’’ The authors attempted to control
for many potential confounding factors, but the task is
monumental and unending. While they measured con-
tinine levels to evaluate smoking exposure, the authors
never measured the metabolic products of caffeine to
determine the actual exposure to caffeine. These studies
were sophisticated and time consuming; however, they
provided conflicting answers to the question of whether
caffeine ingestion represents a risk for SA.
Giannelli et al. (2003) studied the effect of caffeine
consumption and nausea on the risk of miscarriage (SA).
Cases were women in their first pregnancy who were
interviewed about 3 weeks after their pregnancy loss on
average, whereas controls were interviewed at the first
prenatal care visit which typically occurred at a more
advanced gestational age than the SAs. Thus, the burden
of recalling caffeine exposure was not equivalent for
cases and controls, which represents a defect in the study
design. The fact that this was not a prospective study and
the cases were interviewed earlier in pregnancy than the
controls may account for the results. Daily consumption
of 4300 mg of caffeine per day resulted in and increased
risk of SA (odds ratio, OR5 1.9 [1.0–3.6]). The OR was 2.2
in group consuming 4500 mg per day. A much higher
proportion of controls (no SA) reported nausea and
vomiting during their pregnancy. There were other
confounding factors that were not evaluated that
prevented the study to definitively conclude that caffeine
was causally related to the occurrence of SAs.
George et al. (2006) performed a case–control study of
108 women with SAs who had two or more SAs. Controls
were obtained from a population of over 500 women
who had two successful pregnancies and their last
pregnancy was successful. The 108 women had two or
more consecutive miscarriages (cases) and agreed to
Table 2
Estimated Pregnancy Loss in 100 Pregnancies Versus
Time From Conception
Time from
conception
Percent survival
to terma
Percent loss
during intervala
Preimplantation
0–6 days 25 54.55
Postimplantation
7–13 days 55 24.66
14–20 days 73 8.18
3–5 weeks 79.5 7.56
6–9 week 90 6.52
10–13 week 92 4.42
14–17 week 96.26 1.33
18–21 week 97.56 0.85
22–25 week 98.39 0.31
26–29 week 98.69 0.30
30–33 week 98.98 0.30
34–37 week 99.26 0.34
38 weekb 99.32 0.68
The etiology of these abortions is manifold and is listed in
Table 3 (Kajii, 1980).
aData from Kline et al. (1980). An estimated 50 to 70% of all
human conceptions are lost in the first 30 weeks of gestation and
78% are lost before term.
bModified from Schardein (2000).
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participate. Mean caffeine consumption Z300 mg/day
was associated with a 2.7-fold increased odds of repeated
miscarriage (95% CI5 1.1–6.2) in nonsmokers, but not in
smokers. After adjustment for many confounding factors,
the odds of repeated miscarriage was no longer
significantly increased in heavy caffeine users
(Z300 mg/day OR5 1.8, 95% CI5 0.8–3.9). Lack of
control for the pregnancy signal could have provided
another explanation for the association between caffeine
consumption of Z300 mg/day and odds of repeated SA
in nonsmokers. Studies have observed that smokers are
less likely to experience nausea and vomiting during
pregnancy than nonsmokers (Weigel and Weigel, 1989;
Louik et al., 2006). Although the investigators had access
to the nausea and vomiting data it was not utilized to
determine the importance of the pregnancy signal.
Selecting a small population of repeated aborters to
study the risk of abortion from caffeine exposure during
pregnancy complicates the planning and interpretation
of these studies (Tables 3–5).
Greenwood et al. (2010) studied caffeine exposure
during pregnancy, late miscarriage, and stillbirth.
Table 3
Etiology of Abortion
1. Chromosomal abnormalities: pre-conceptional or periconceptional etiology
2. Embryos and fetuses with severe congenital malformations or growth retardation
3. Endometriosis
4. Lupus anticoagulant (antiphospholipid antibodies) and other immunological problems related to reproduction
5. Cervicitis; bacterial or viral infection (Kriel et al., 1970; Mead, 1989)
6. Uterine abnormalities: subserosal myoma or hematoma, infantile uterus, bifid uterus, IUD, etc. (8–10% of recurrent aborters)
7. Some teratogens, especially those with cytotoxic properties and endocrine disrupters (RU 486)
8. Maternal diabetes, alcoholism, hypothyroidism, illicit drug abuse, maternal phenylketonuria, hemorrhagic diatheses, and many other
chronic and acute maternal diseases
9. Luteal phase hormonal deficiency
10. Trauma, IUDs, lightening and other rare miscellaneous events
11. Hypersecretion of LH
12. Hyperandrogenemia
13. Hyperprolactinemia
14. Autoimmune thyroid disease
15. Thrombophilic abnormalities other than antiphospholipid antibody
16. Vitamin B 12 deficiency
17. Elevated glutathione levels
18. Dietary factors; decreased with fruits and vegetable, increased with diet rich in fats
19. Twenty-seven percent of women with habitual abortion had a mutation G1691A in Factor V gene (Leiden mutation) of mutation
C677T in the methylenetetrahydrofolate reductase gene. The Leiden mutation may play a considerable role for women having
primary recurrent abortions
20. Fourteen percent of women with unexplained recurrent abortion show highly skewed X-chromosome inactivation, which shows that
they are carriers of X-linked lethal traits
21. IgG auto anti-laminin antibodies and recurrent abortion
22. HLA-G genotype and recurrent abortion
23. TH 1 type response associated with recurrent abortion (cytokines)
Table 4
Etiology of Human Congenital Malformations Observed During the First Year of Lifea
Suspected cause Percent of total
Unknown 65 to 75
Polygenic
Multi factorial (gene-environment interactions)
Spontaneous errors of development
Synergistic interactions of teratogens
Genetic 10 to 25
Autosomal and sex-linked genetic disease
New mutations
Cytogenetic (chromosomal abnormalities)
Environmenta 10
Maternal conditions: Alcoholism; diabetes; endocrinopathies; phenylketonuria; smoking and nicotine;
starvation; nutritional, hyperthermia
4
Infectious agents: Rubella, toxoplasmosis, syphilis, herpes, cytomegalic inclusion disease, varicella,
Venezuelan equine encephalitis, parvo virus B19
3
Mechanical problems (deformations): Amniotic band constrictions; umbilical cord constraint; disparity in
uterine size and uterine contents
1 to 2
Chemicals, prescription drugs, high dose ionizing radiation 2 to 3
aAdapted from Brent (1976, 1985, 1999, 2004, 2008) and Brent and Holmes (1988).
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According to the authors, ‘‘there are no large well-
conducted effectiveness studies’’. The study population
included 2643 pregnant women, aged 18 to 45 years of
age who were admitted to the study between 8 and 12
weeks gestational age. The pregnancies were monitored
for late SAs and stillbirth. Total caffeine intake was
estimated from all possible sources in the first trimester
and throughout pregnancy. The adjusted data revealed a
strong association between caffeine intake in the first
trimester and subsequent late miscarriage between 12
and 24 weeks and stillbirth after 24 weeks. The cases
ingested an average of 145 mg of caffeine per day, while
the controls averaged 103 mg per day. All the OR were
increased for the cases, and none of the increased OR’s
were statistically significant. The authors support the
conclusion that caffeine intake should be limited during
pregnancy. Unfortunately, the investigators did not
adjust the data for the pregnancy signal. The investiga-
tors provided no mechanism for caffeine exposure in the
first trimester to produce a pregnancy loss many weeks
later or even in the third trimester.
Karypidis et al. (2006) performed a case–control study
comparing the risks of SA associated with CYP1B1
polymorphisms and a possible interaction of these
polymorphisms with caffeine consumption. CYP1B1 is
an enzyme that is known to take part in the metabolism
of many steroid hormones as well caffeine. Caffeine
consumption was assessed and categorized in mg/day
as 0 to 99, 100 to 299, 300 to 499, and Z500. Nausea was
recorded by week of gestation and scored as never (0),
sometimes but not daily (1), daily but not all day (2), and
daily all day (3). Vomiting was recorded by week of
gestation as never (0), sometimes but not daily (1), and
daily (2). Mean weekly scores were calculated for each
symptom. Smoking status was determined based on
plasma continine levels, with smokers defined as those
with levels 415 ng/ml. Overall, there was a significant
interaction between homozygosity for Val and caffeine
intake, such that compared to women who were
homozygous for Leu and who consumed o100 mg of
caffeine per day, the odds of miscarriage was signifi-
cantly elevated only in women homozygous for Val and
who consumed either 100 to 299 mg caffeine per day
(OR5 2.36 [95% CI5 1.39–4.98]) or 4500 mg/day
(OR5 3.61; 95% CI5 1.36–9.61); for genotype strata
Leu/Leu and Val/Leu, no significant associations
were observed between increasing levels of caffeine
consumption and the increased risk of miscarriage. No
significant interaction was observed between caffeine
ingestion and smoking. The many confounding issues
that were evaluated in the analyses limited the ability to
detect associations.
Khoury et al. (2004) conducted a cohort study within a
prospective cohort of women with type 1 diabetes who
were pregnant or planning a pregnancy. A total of 191
pregnancies were observed between 1978 and 1985. This
is a small sample size for a SA study. Consumption of
one or more cups of caffeinated beverages per day
during the first trimester of pregnancy was reported by
54% of the women. Clinically recognized SAsr20 weeks
were identified in 12%. Compared to no caffeine intake,
the OR were 3.8 (95% CI5 0.8–16.9) for first trimester
consumption of 1 to 2 cups of caffeinated beverages per
day and 5.5 (95% CI5 1.2–22.0) forZ3 cups per day. The
difficulties with this study are that the investigators did
not control for the pregnancy signal and their methodology
for calculating caffeine consumption was imprecise.
Klonoff-Cohen et al. (2002) evaluated the risk of
miscarriage in 221 couples undergoing in vitro fertiliza-
tion (IVF) and gamete intra-Fallopian transfer (GIFT).
There were no observed associations for miscarriage with
first trimester caffeine use. The fact that there was an
increased miscarriage risk for preconception exposure to
caffeine makes little sense because caffeine has minimal
mutagenic potential and is unlikely to result in an
increase in chromosome aberrations resulting in preg-
nancy loss. Assisted Reproductive Technology (ART)
patients are seeking these programs because they already
have reproductive problems. The failure rate in these
programs has a wide standard deviation. With this small
population the task to determine the contribution of
caffeine to the incidence of SA is very difficult.
Maconochie et al. (2007) studied risk factors for first
trimester miscarriage (SA). The investigators determined
that pregnant women who experienced nausea were
strongly associated with a reduced odds for a miscar-
riage (OR5 0.3; 95% CI5 0.25–0.36) for mild or moderate
nausea and (OR5 0.07; 95% CI 0.04–0.14) for severe
nausea, defined as frequent vomiting. When nausea was
controlled for exposures of 4500 mg/day, with OR of
1.14 (95% CI5 0.79–1.66). The authors concluded that if
you did not control for nausea and vomiting in the
pregnant population, the studies that demonstrate a
positive association of caffeine ingestion with SA may
Table 5
Principles of Teratology
1. Exposure to teratogens follows a toxicological dose–response curve. There is a threshold below which no teratogenic effect will be
observed, and as the dose of the teratogen is increased, both the severity and frequency of reproductive effects will increase
2. The embryonic stage of exposure is critical in determining what deleterious effects will be produced and whether any of these effects
can be produced by a known teratogen. Some teratogenic effects have a broad, and others, a very narrow period of vulnerability.
The most sensitive stage for the induction of mental retardation from ionizing radiation is from the 8th to 15th week of pregnancy, a
lengthy period. Thalidomide’s period of vulnerability is approximately two weeks
3. Even the most potent teratogenic agent cannot produce every malformation
4. Most teratogens have a confined group of congenital malformations that result after exposure during a critical period of embryonic
development. This confined group of malformations is referred to as the syndrome that describes the agent’s teratogenic effects
5. While a group of malformations may suggest the possibility of certain teratogens, they cannot definitively confirm the causal agent
because some teratogenic syndromes mimic genetic syndromes. On the other hand, the presence of certain malformations can
eliminate the possibility that a particular teratogenic agent was responsible because those malformations have not been
demonstrated to be part of the syndrome or because the production of that malformation is not biologically plausible for that
particular alleged teratogen
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not be valid. While there are many problems in the
design of this study, the investigators did demonstrate
that caffeine exposure was not associated with the
increased risk of SAs if the data were adjusted for the
confounding effect of the Pregnancy Signal.
In the Rasch (2003) studies, smoking, alcohol con-
sumption, and caffeine ingestion were evaluated as risk
factors for SA. Unfortunately, the investigator made no
attempt to control for the pregnancy signal. An important
and interesting concern is the possibility of evaluating
fetal exposure following fetal demise. Since fetal demise
may occur weeks before a SA is recognized, caffeine
consumption may return to typical intake levels as
pregnancy symptoms abate, artificially inflating esti-
mates of caffeine use during the time period that may not
be relevant. This was a large study of 303 women with
documented SAs and 1168 controls. Almost half the
women reported heavy caffeine consumption. SAs were
increased in the group exposed to 4375 mg of caffeine
per day (OR5 2.2 [1.5–3.2]). Without controlling for
nausea and vomiting symptoms it is not possible to
verify a causal relationship to the caffeine exposure.
Sata et al. (2005) studied caffeine intake, CYP1A2
polymorphism, and the risk of recurrent pregnancy loss
in a case–control study that reported no overall associa-
tion between caffeine intakeZ300 mg/day and recurrent
pregnancy loss (OR5 1.82; 95% CI5 0.72–4.58). The
concept of the investigators was that polymorphism of
CYP1A2 could result in populations with the ability to
rapidly metabolize caffeine and therefore be able to
tolerate higher exposures of caffeine. Unfortunately, the
results were not decisive. No associations were observed
among women with other CYP1A2 genotypes (CC1CA)
(OR5 1.03 [95% CI5 0.29–3.70] for Z300 mg/day com-
pared to 0–99 mg/day). There were many limitations to
the study including small sample size; the pregnancy
signal was not evaluated and no associations were
observed between caffeine intake and recurrent preg-
nancy loss when analyses were conducted without
regard for CYPIA2 polymorphisms. While the concept
that formed the basis of this study makes biological
sense, the results do not definitively support the
hypotheses for an interactive effect of heavy caffeine use
and CYP1A2 genotype on recurrent pregnancy losses.
Savitz (2008) evaluated caffeine consumption and the
risk of SA (r20 weeks of gestation) occurring in a cohort
of 2407 pregnant women. Daily caffeine consumption was
determined before pregnancy, four weeks after the last
menstrual period and at the time of the interview. There
was an association of an increased risk of SA obtained
from the caffeine data that were provided after the SA had
occurred. However, there was no increased risk of SA
utilizing the caffeine consumption data that were obtained
before the SA had occurred. The obvious recall bias
undermined the positive results and the investigators
concluded that the study showed no association between
coffee consumption and total caffeine intake before or
during pregnancy and risk of SA up to 20 weeks of
gestation. Low level of caffeine exposure in study
population restricted ability to evaluate intake 4300mg/day.
The results of this study do not support an association
between SA and caffeine intake before or during
pregnancy at the caffeine exposures that were studied.
Tolstrup et al. (2003) performed a nested case–control
study of SA within the first 28 weeks of pregnancy in a
large cohort of young, nonpregnant women sampled
from the Copenhagen population. The daily caffeine
consumption was divided into the following groups:
o75 (the reference group), 75 to 300, 301 to 500, 501 to
900, and 4900 mg per day. There were 303 SAs that were
ascertained. This information was obtained in a follow-
up interview or from the hospital record. The validity of
the study would have been improved if all the SAs had
been confirmed from the hospital record and the study
population had been assessed for the pregnancy signal.
Only the 900 mg/day estimated exposure was statisti-
cally associated with ‘‘abortion’’ in their study (OR5 1.7
[1.0–3.0]). There was no increased risk in the 300 and
500 mg per day groups. This study was unusual in
that pregnancy losses up to 28-week gestation were
labeled as SA
Wen et al. (2001) studied the association of maternal
caffeine consumption with SA. This study was a
prospective cohort study of SAs in the first trimester of
pregnancy. Caffeine ingestion was evaluated by periodi-
cally utilizing a food intake questionnaire. The prelimin-
ary results indicated that the risk of SA was elevated with
exposures between 100 to 300 mg/day (OR5 2.0; 1.0–4.1)
and greater than 300 mg/day. The risk of SA was 4.11
times higher in women who did not report nausea
during the first trimester compared to those who did
(29.6 vs. 7.2%). There was no statistically increased risk in
the groups that ingested less than 300 mg/day and a very
high RR of 5.4 in the group that ingested 4300 mg/day.
There was incomplete evaluation of confounding factors.
Small number of SAs in all categories of caffeine
consumption limited the ability to detect associations.
There was lack of control for the pregnancy signal
although the questionnaire did request information
concerning the presence of nausea.
Weng et al. (2008) performed a prospective cohort
study with data that had been utilized for several SA
studies, so it is not clear whether the initial planning and
collection of data had the intention to study the SA risk of
caffeine exposure during pregnancy. One thousand and
sixty-three (1063) women consented to be part of the
study and completed the in-person interview soon after
confirmation of pregnancy (median gestational age at
interview was 10 weeks). Cox proportional hazards
models were used to compare rates of miscarriage by
caffeine exposure status, adjusted for maternal age, race,
education, family income, marital status, previous mis-
carriage, nausea and vomiting since last menstrual
period, smoking status, alcohol drinking, Jacuzzi
use, and exposure to magnetic fields during pregnancy.
The risk of SA was increased in the exposure group
of 4200 mg/day. It is interesting that these authors
have already reported that magnetic fields increase the
risk of miscarriage using the same population of pregnant
patients (Li et al., 2002). In some instances the authors
also determined that a miscarriage had occurred if the
only source of the information was from the mother. In
other words, they may not have medical documentation
that a miscarriage had occurred. Exposures of 4200 mg/
day of caffeine had OR of 2.23 (95% CI5 1.34–3.69).
However, when the subjects were identified as having the
pregnancy signal and were in the group exposed to
4200 mg/day, the risk of SA was not increased.
Signorello et al. (2001) studied the effect of caffeine
consumption and nausea on the risk of miscarriage (SA).
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This study was conducted utilizing the same case–
control study population reported in Cnattingius et al.
(2000). One hundred one (101) chromosomally normal
SAs that occurred between 6 and 12 weeks of gestation
were compared to the 953 controls that were matched by
week of gestation and area of residence from the 562
control cases. With the goal of evaluating the variability
in caffeine metabolism as a risk factor for SAs, the
authors estimated the activity levels of two enzymes,
cytochrome P4501A2 (CYP1A2) and N-actyltransferase 2
(NAT2) given both are involved in the metabolism or
detoxification of many drugs including caffeine. This
was a well planned and work intensive study to
determine whether pregnant mothers with the ability to
rapidly metabolize caffeine would have a lower risk for
SA at all caffeine exposure levels. Using blood samples
collected at the time of the SAs for cases and at the time
of the interview for controls, polymorphisms of the
NAT2 gene and CYP1A2 phenotypes were determined. It
is not clear why the authors did not use the blood
samples to determine the metabolic products of caffeine
metabolism rather than the complicated indirect CYP1A2
analysis. The investigators reported that the women with
high CYP1A2 activity had an increased risk for SAs in the
100 to 299 mg/day and theZ300 mg/day groups, but no
increase in SA risks among the subjects with low
CYP1A2 activity. The results were not in the anticipated
direction given that the authors’ hypothesis was that
caffeine would be more strongly associated with SA
among slow metabolizers due to slower caffeine clear-
ance. While these studies were sophisticated and time
consuming, they have provided conflicting answers to
the question of whether caffeine ingestion represents a
risk for SA.
Zusterzeel et al. (2000) performed a case–control study
of recurrent early pregnancy loss that evaluated associa-
tions with polymorphisms in glutathione S-transferase
(GST) and cytochrome P450 genes. The authors postu-
lated that genetic polymorphisms in these genes may
reflect impaired drug metabolism, resulting in an
increased susceptibility to adverse outcomes from
exposures to caffeine. The case included pregnant
women who had at least two unexplained consecutive
SAs occurring at o17 weeks of gestation. Coffee
consumption was reported by the authors in the
following categories, 1 to 5, 5 to –10, and 410 cups of
coffee per day. The data show no observed associations
between daily coffee intake and recurrent pregnancy loss
for 1 to 5 cups and for 45 cups compared to noncoffee
drinkers. Although the GSTP1b-1b polymorphism ap-
peared to be more common among women with
recurrent early pregnancy loss, the limited data pre-
sented in this paper offer no evidence to implicate a
specific role for coffee intake via direct or interactive
effects with GST polymorphisms.
Summary of caffeine exposure and the risk
of SA (miscarriage). Since 2000, 17 epidemiological
studies have been published dealing with the risk of SA
from exposure to caffeine. Ten were case–control studies
and the number of cases ranged from 58 to 953. There
were six prospective cohort studies. One study was a
nested control study. Only one of the studies measured
the serum levels of caffeine or its metabolites to
determine the actual caffeine exposure. With regard to
the exposure that was evaluated, namely number of
caffeine-containing beverages for various time periods,
there was no increased risk of miscarriage in the majority
of studies in women who drank three cups of coffee or
less per day. However, there were a few studies with
increased risks for miscarriage in the lowest exposure
groups.
The most serious criticism of the studies dealing with
SA is that 11 of the 17 studies failed to evaluate the
importance of the Pregnancy Signal (Cnattinglus et al.,
2000; Wen et al., 2001; Klonoff-Cohen et al., 2002;
Giannelli et al., 2003; Rasch, 2003; Tolstrup et al., 2003;
Khoury et al., 2004; Sata et al., 2005; George et al., 2006;
Weng et al., 2008; Greenwood et al., 2010).
Evaluating the subjects in an epidemiology study with
regard to the pregnancy signal allows the investigators to
identify subjects with high and low reproductive risks
(Weigel and Weigel, 1989; Lawson et al., 2004; Louik
et al., 2006; Boylan et al., 2008).
Positive associations of maternal coffee drinking or
caffeine ingestion during pregnancy and the increased
risk of SAs have been reported in epidemiological studies
or reviews (Christian and Brent, 2001; Leviton and
Cowan, 2002; Signorello and McLaughlin, 2004; Infante-
Rivard, 2007; CARE Study Group, 2008; Weng et al., 2008).
Other reviews have not found such associations, and
many of the associations observed may be attributable to
confounding effects of maternal cigarette smoking or
nutritional factors (Christian and Brent, 2001; Leviton and
Cowan, 2002; Signorello and McLaughlin, 2004; Bech
et al., 2007; Maconochie et al., 2007; Savitz, 2008).
The epidemiological studies evaluating the risk of SAs
from caffeine exposure have been inconsistent. Reports
of maternal consumption of caffeine at the level of
o300 mg/day has been associated with an increased risk
for SAs. Other studies have reported that exposures of
500 to 900 mg/day are not associated with and increased
risk of SAs. Which result is correct? Unfortunately, none
of the epidemiology studies cited the nonhuman mam-
malian studies dealing with caffeine exposure and SA.
The animal studies reveal that the wide range of human
exposures when utilized in animal reproductive studies
do not result in increased pregnancy loss in mammalian
reproductive studies. (See later sections.)
Congenital Malformations
The principles of teratology can be useful for planning
epidemiology studies as well as interpreting the results
(Table 5).
It is important to be cognizant of the fact that drugs and
chemicals account for only a small percent of environ-
mentally produced congenital malformations and that
almost all teratogens produce a constellation of effects
that is identified with the teratogen (Tables 4 and 5). This
should indicate to physicians, epidemiologists, and
scientists that determining whether a drug or chemical
is responsible for increasing the risk for CMs is not a
simple task. Statistical associations do not necessarily
indicate causal associations! (Nelson and Forfar, 1971;
Fedrick, 1974; Heinonen et al., 1977; Borlee et al., 1978;
Linn et al., 1982; Rosenberg et al., 1982; Kurppa et al.,
1983; James and Paull, 1985; Pieters, 1985; Olsen et al.,
1991; Natsume et al., 2000; Torfs and Christianson, 2000;
Browne, 2006; Bille et al., 2007; Browne et al., 2007;
Mongraw-Chaffin et al., 2008).
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Malformations were not more frequent than expected
in these caffeine epidemiology studies performed before
the year 2000 (Nelson and Forfar, 1971; Heinonen et al.,
1977; Linn et al., 1982; Rosenberg et al., 1982; Kurppa
et al., 1983; Olsen et al., 1991). In two other case–control
studies, significant associations were observed with the
consumption of caffeinated beverages during pregnancy
among mothers of 464 anencephalic infants and 190
children with various malformations (Fedrick, 1974;
Borlee et al., 1978).
In studies performed in 2000 and thereafter there were
11 epidemiological publications (Natsume et al., 2000;
Torfs and Christianson, 2000; Browne, 2006; Bille et al.,
2007; Browne et al., 2007; Mongraw-Chaffin et al., 2008;
Collier et al., 2009; Johansen et al., 2009; Miller et al., 2009;
Schmidt et al., 2009).
Bille et al. (2007) reported the association between oral
clefts and first trimester maternal lifestyle factors
utilizing the Danish record population that includes
100,000 pregnancies. There were 192 mothers in this
cohort that gave birth to a child with an oral cleft. The
investigators reported that first trimester smoking was
associated with an increased risk of clefting, OR5 1.5
(95% CI5 1.05–2.14). Evaluation of the risks of coffee, tea,
and alcohol found OR 41.0; however, the data were not
statistically significant. The authors reported an associa-
tion of drinking five or more cups of tea per day early in
pregnancy among the mothers of 58 children with cleft
palate only, OR5 2.9, 95% CI (1.1–5.6) for infants with
isolated only cleft palate. No significant association was
found with maternal coffee or cola drinking in this study
among the mothers of children with cleft palate, and no
associations were found among the mothers of 134
infants with cleft lip with or without cleft palate and
consumption of any caffeinated beverage. Bille et al.
concluded, ‘‘There is no solid evidence to support caffeine
as a risk factor in humans for oral clefts’’ (Rosenberg
et al., 1982; Levitan and Cowan, 2002; Nawrot et al.,
2003). The authors also conducted sub-analyses restricted
to nonsyndromic cases, which may be etiologically
distinct from oral clefts that occur as part of a syndrome.
In fact, this may be the incorrect approach because most
teratogens produce syndromes and genetic abnormalities
are an important contributor to the occurrence of isolated
cleft lip and cleft palate.
Browne (2006) performed a systematic review of
epidemiological studies published before 2006 and
concluded that there is no evidence that maternal
caffeine consumption during pregnancy increases the
risk of congenital anomalies in infants.
Browne et al. (2007) reported no consistent association
with maternal caffeine consumption early in pregnancy
in a case–control study of 4,196 infants and 3,957 controls
with various types of cardiac malformations utilizing the
data from the National Birth Defects Prevention Study
Program. In fact, in the analysis of the atrial septal defect
incidence associated with coffee intake, the OR5 0.46
(CI5 0.28–0.75) indicated that there was a lower risk
associated with caffeine exposure. The investigators
concluded that the results indicated that caffeine is
unlikely to be causally related to the occurrence of
congenital heart malformations.
Collier et al. (2009) reported a significant association
with maternal intake of 200 mg of caffeine per day or more,
among the mothers of 175 infants with cleft lip with or
without cleft palate and other congenital anomalies
(OR51.7; 95% CI51.0–2.9). For mothers who consumed
10 to 99 mg of caffeine per day, there was also a significant
association with maternal intake of 100 mg of caffeine per
day or more among the mothers of 657 infants with
isolated cleft palate only (OR51.2; 95% CI5 1.0–1.6). The
lack of correction for multiple comparisons and lack of a
dose effect with these associations makes a causal relation-
ship less likely. Selecting isolated clefting malformations as
potentially being produced by in utero exposure to caffeine
is problematic. This malformation, which has an important
genetic contribution and is frequently an isolated mal-
formation, is unlikely to result from exposure to a
teratogenic agent, since known causes of cleft palate from
teratogens are syndromic (anticonvulsants, alcohol, ami-
nopterin, and retinoids).
Johansen et al. (2009) reported an association with
maternal caffeine consumption (for all beverages) during
the first three months of pregnancy in a Norwegian case–
control study of 573 children with isolated cleft lip with
or without cleft palate (OR5 1.47; 95% CI5 1.05–2.07).
There were 763 randomly selected controls. For mothers
who consumed 40 but o3 cups of coffee per day;
OR5 1.39 (95% CI5 1.01–1.92). For mothers who con-
sumed three or more cups of caffeine containing
beverages per day the OR5 1.59 (95% CI5 1.05–3.59).
There was no association of coffee consumption early in
pregnancy among the offspring with cleft palate whose
mother drank 43 cups day in this study, OR5 0.96, CI
(0.55–1.67). There was a negative (i.e., a protective)
association with maternal tea drinking among mothers
of the children with isolated cleft lip with or without cleft
palate (OD5 0.72; 95% CI5 0.30–0.94) for mothers who
consumed three or more cups of tea per day, and no
association with maternal cola consumption or with
estimated daily caffeine consumption from all sources in
either group. The author’s conclusion was, ‘‘There was
little evidence of an association between caffeine and
clefts when all sources of caffeine were considered.’’
Miller et al. (2009) studied ‘‘Maternal exposure to
tobacco smoke, alcohol, and caffeine, and the risk of
anorectal atresia.’’ The data utilized in this study are
from the National Birth Defects Prevention Study
(NBDPS). There were 464 infants with the diagnosis of
anorectal atresia and 4,940 controls. There were three
exposure categories: 10 to 99, 100 to 299, and 4300 mg/
kg/day. The OR for all three exposure groups were 1.4,
1.3, and 1.5 respectively and all three ORs were
significant. There was no increasing risk with increasing
exposure. The observed association of isolated anorectal
atresia with caffeine is unlikely to be causally related to
caffeine exposure (Table 5).
Mongraw-Chaffin et al. (2008) conducted a nested
case–control study of cryptorchidism among children
born to mothers enrolled in the Collaborative Perinatal
Project between 1959 and 1967. The diagnosis had to
persist beyond two years of age in order to be included in
the study. The investigators found an association with
maternal consumption of the equivalent of three or more
cups of coffee per day (OD5 1.43, 95% CI5 1.06–1.93).
Selecting isolated cryptorchidism as a malformation that
may be produced by in utero exposure to caffeine is
problematic. This malformation, which has an important
genetic contribution and is frequently an isolated mal-
formation, is unlikely to result from exposure to caffeine.
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Natsume et al. (2000) performed a case–control study
of cleft lip and palate that included 306 cases of cleft lip,
cleft palate, or both matched to 306 controls. The protocol
of this report was lacking in detail. The investigators
described the caffeine exposure in cups per week, which
is inadequate. Although the analyses did not indicate
that there was an increased risk of cleft lip and palate this
study will not be included in the final analysis.
Slickers et al. (2008) studied maternal caffeine con-
sumption and the risk of bilateral renal agenesis and
renal hypoplasia. The data utilized in this study are from
the National Birth Defects Prevention Study (NBDPS).
Renal agenesis and hypoplasia has many etiologies,
including genetic causes. The results were inconclusive,
in that there was not a statistical increased risk with
caffeine exposure. However, there were only 75 renal
malformations in this case–control study, which makes
any definitive interpretation problematic.
Schmidt et al. (2009) studied maternal caffeine con-
sumption and the risk of neural tube defects (NTDs). The
data utilized in this study are from the National Birth
Defects Prevention Study (NBDPS). Total average daily
caffeine dietary consumption was obtained during the
year before pregnancy occurred for 768 mothers with
children with NTDs and 4,143 control mothers and
infants without NTDs. Positive associations were
observed between caffeine consumption and spina bifida
(OR5 1.4; 95% CI5 1.1–1.9). Interestingly, caffeinated tea
consumption had a protective association (OR5 0.7,
CI5 0.6–0.9). While most of the OR were greater than
one, few were statistically significant. Furthermore, the
mothers with the highest intake of caffeine (200–299 mg/
day, 4300 mg/day) did not have a statistically signifi-
cant increased OR for NTDs. The discussion section of
this publication is extensive and has numerous hypoth-
eses as to why the findings indicate that caffeine causes
NTDs. No mention is made of evaluating the ‘‘pregnancy
signal’’ and its role in separating the at-risk from the low
risk population. Since the vast majority of teratogenic
drugs produce a teratogenic syndrome and not isolated
malformations such as NTDs, their findings are not
supported by one of the basic teratology principles
(Table 5). The authors did not review the animal
literature, which indicates that caffeine does not cause
isolated NTDs. The first sentence in this publication
states, ‘‘Animal studies demonstrate teratogenic
effects of caffeine and human studies are inconclusive.’’
The first report of the teratogenicity of caffeine was
published in 1960 and the dose administered was
250 mg/kg (Nishimura and Nakai, 1960). Animal
studies result in teratogenesis (Christian and Brent,
2001), if the exposures are far above any possible human
exposure from caffeine consumption and that epidemio-
logical literature demonstrates that caffeine is unlikely to
be a human teratogen from human dietary exposures.
The authors do not report the folic acid levels in their
patient populations and therefore cannot discuss the
important nutritional data with regard to the role of
nutrition as an etiological factor in the patients with
NTDs in their study.
Torfs and Christianson (2000) examined some of the
environmental risks for the occurrence of Down syn-
drome. The study was a population-based case–control
study that identified 997 Down syndrome cases from the
California Birth Defects Monitoring Program and 1,007
live born nonmalformed controls from the general
population. Six months after delivery, the mothers were
asked about their consumption of coffee, tea, and soft
drink ‘‘around the time of conception.’’ Since Down
syndrome is a chromosome abnormality due to the
presence of an extra chromosome 21 during the matura-
tion of the sperm or egg, caffeine, exposures during
embryonic development cannot produce this abnormal-
ity. Preconception exposures to caffeine would be very
unlikely to affect the maternal ova because caffeine is not
considered to be mutagenic. A protective association
between heavy coffee intake (Z four or more cups per
day) and Down syndrome was observed among non-
smokers (OR5 0.48; 95% CI5 0.28–0.82) but not smokers
(OR5 1.64; 95% CI5 0.80–3.36). This study is of interest,
but does not contribute to the evaluation of whether
caffeine has a teratogenic effect. One of the several
hypotheses generated by the investigators was that
caffeine may have caused SAs of Down syndrome
embryos, thus decreasing the incidence of Down syn-
drome in the high caffeine exposure group.
Summary of the risk of congenital malforma-
tions from dietary exposure to caffeine. It is very
unlikely that the usual or even high exposures of dietary
caffeine increases the risk of birth defects for pregnant
mothers exposed to caffeine. Not one investigator has
published the constellation of developmental abnormal-
ities that constitutes the ‘‘caffeine teratogenic syndrome’’
in humans (Table 5). None of the epidemiologists have
carefully examined the animal teratology or animal
toxicokinetic literature to determine the magnitude of
exposure necessary to produce congenital malforma-
tions. Schmidt et al. (2009) cited the original publication
indicating that caffeine was teratogenic in the mouse
(Nishimura and Nakai, 1960). These investigators admi-
nistered 250 mg/kg i.p. to pregnant mice that resulted in
vascular disruptive malformations at exposures that are
never reached in humans from even high exposures of
dietary caffeine.
Fetal Weight Reduction (Small for Gestational
Age [SGA])
Before the year 2000, several studies were reported that
indicated that caffeine exposure during pregnancy was
associated with fetal growth retardation (Mau and
Netter, 1974; Martin and Bracken, 1987; Fenster et al.,
1991; Peackock et al., 1991; Vlajinac et al., 1997). Other
investigators have indicated that smoking may be an
important confounder in caffeine fetal growth studies
(Beaulac-Baillargeon and Desroisiers, 1987). Studies have
also reported that the results did not indicate that
caffeine exposure during pregnancy reduced fetal
growth (Linn et al., 1982; Cook et al., 1996; Committee
on Toxicity, 2001).
During the years from 2000 to 2010, 17 articles were
published evaluating the risk of maternal caffeine
exposure and fetal weight reduction (Grosso et al.,
2001, 2006; Clausson et al., 2002; Klebanoff et al., 2002;
Balat et al., 2003; Bracken et al., 2003; Ørskou et al., 2003;
Vik et al., 2003; Parazzini et al., 2005; Santos et al., 2005;
Tsubouchi et al., 2006; Bech et al., 2007; Diego et al., 2007;
Infante-Rivard, 2007; Care Study Group, 2008; Xue et al.,
2008; Bakker et al., 2010).
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Bakker et al. (2010) examined the associations of
maternal caffeine intake, based on coffee and tea
consumption, with fetal linear growth and fetal weight
measurements in each trimester of pregnancy and the
risk of adverse birth outcomes. There were 7,346
pregnant women participating in a population-based
prospective cohort study from early pregnancy onward
in the Netherlands (2001–2005). Caffeine intake in the
first, second, and third trimesters was on the basis of
coffee and tea consumption and was assessed by
questionnaires. Fetal linear growth measurements were
repeatedly measured by ultrasound. Information about
birth outcomes was obtained from hospital records. The
investigators observed no consistent associations of
caffeine intake with fetal head circumference or esti-
mated fetal weight in any trimester. Higher caffeine
intake was associated with smaller first-trimester crown-
rump length, second- and third-trimester femur length,
and birth length (p for trend o0.05). Offspring of
mothers who consumed 46 caffeine units/day
(540 mg) tended to have increased risks of small-for-
gestational-age infants at birth. The authors concluded
that caffeine intake of 46 units/day during pregnancy is
associated with impaired fetal length. Caffeine exposure
might preferentially adversely affect fetal skeletal growth
and that further studies are needed. The actual data are
more important than the conclusions. In the small group
of 133 women who had the equivalent of 6 cups of coffee
per day, the femur was smaller by 0.5 mm in the third
trimester and the crown rump length (CRL) was reduced
by 4.54 mm in the first trimester. There was no effect on
birth weight, head circumference, or prematurity inci-
dence. The CRL at term is not available in the
publication. No mention is made of controlling for the
pregnancy signal. The average birth weight was over
3,400 g. The only positive group for shortening of length
(in millimeters) was the women who ingested 6 or more
(units, 540 mg) cups of coffee per day. It was not
determined whether the reduced length was recoverable
or of any clinical significance. This study is more
important because of the negative findings, rather than
the minimal positive findings. Caffeine exposure at every
exposure had no effect on birth weight. There was no
increase in SGA babies in this study.
Balat et al. (2003) recruited a group of smokers (n5 60)
and nonsmokers (n5 63) who delivered at full-term
(37–41 weeks) to evaluate the effect of caffeine intake on
newborn and placental characteristics. The investigators
obtained the caffeine intake based on the average
number of cups of coffee and tea consumed per day.
Based on the intake, the mothers were divided into two
groups: o300 mg/day or 4300 mg/day, assuming
107 mg of caffeine for each cup of coffee and 34 mg for
each cup of tea. This study did not attempt to control for
other important confounders such as maternal age,
alcohol use, and gestational age at birth. The difference
in birth weight between the 4300 mg/day versus the
o300 mg/day group was 128 g. The results do not
definitively suggest that the caffeine was responsible
for this very small, clinically insignificant weight
difference.
Bech et al. (2007) randomly assigned women
(n5 1,197) to caffeinated or decaffeinated instant coffee
during the last half of pregnancy. The pregnancies were
followed to evaluate differences in gestational age and
mean birth weight. Participants were provided unlimited
amounts of coffee, either caffeinated or decaffeinated as
assigned. They were also free to consume other sources
of coffee and caffeinated beverages. It would appear that
this study should have been altered once the investiga-
tors realized that there were no real exposed and control
groups. The possible interaction between smoking
and caffeine consumption on birth weight is unconvin-
cing without presentation of the results by compliance
or, preferably, by actual caffeine consumption. The
investigators reported a 263 g weight reduction in the
newborns from exposure to caffeine, which is clinically
significant.
Bracken et al. (2003): This prospective cohort study
included 2291 pregnant women r24 gestational weeks
from clinics and obstetric practices. Caffeine exposures
were evaluated as urinary caffeine and self reporting of
caffeine ingestion during early and late pregnancy. The
rates of IUGR (8.4%), low birth weight (4.7%), and
preterm birth (7.0%) were lower in this cohort than in the
general US population for the year 2000 (10, 6, and 11.6%,
respectively) (Leo´n et al., 2002). There is minimal
evidence in this publication to indicate that caffeine use
during early or late pregnancy is related to low birth
weight.
Care Study Group (2008) performed a prospective
longitudinal observational study to examine the associa-
tion of maternal caffeine intake with ‘‘fetal growth
restriction.’’ During the 8th to 12th week of pregnancy
2635 women were recruited for the study. Assessments of
(1) caffeine and (2) smoking and tobacco exposure were
performed by self-reporting and by measuring caffeine
and cotinine in the saliva. This was a large and ambitious
project. There were four categories of exposure (o100,
100–199, 200–299, 4300 mg of caffeine per day). The
adjusted OR were calculated for the 12 groups that were
evaluated. There were four groups that were not
significant. The remaining OR’s were significant with
five of the OR’s having a CI lower than 1.0. Placing this
data into clinical perspective, the average difference in
birth weight between the caffeine exposed and the
controls in the 12 groups ranged between 21 and 89 g.
Those differences in birth weight are the equivalent to
less than one to three ounces, and are clinically
insignificant. The authors describe these findings as
associations; however, their clinical recommendations
infer that the caffeine has a causal relationship and not
just an association. Their recommendation is, ‘‘Sensible
advice would be to reduce caffeine intake before
conception and throughout pregnancy.’’ More appropri-
ate advice would be to also stop smoking, limit alcohol
consumption, limit vigorous exercise, limit calorie
restriction, nutritional fads, and recreational drugs. This
was a very large and comprehensive study; however, the
investigators ignored the evaluation of the pregnancy
signal for collating pregnancies into high risk and low
risk categories for reproductive and developmental
problems, which is a serious deficiency.
Clausson et al. (2002): A population of patients that
had been part of a SA study (Cnattingius et al., 2000) was
followed to evaluate the effects of caffeine use on the
birth weight of the newborns. Caffeine intake was
obtained for the first six weeks of gestation, second
trimester, and for a portion of the third trimester. There
were four exposure categories, 0 to 99, 100 to 299, 300 to
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499, or Z500 mg/day. There were no differences in birth
weights in the five different, caffeine intake categories.
Diego et al. (2007): Birth weights were obtained from
the medical records of 452 participants who were
recruited between 20 and 28 weeks of gestation. The
data pertaining to the caffeine exposure are unclear and
there was no attempt to evaluate confounding factors.
The exposures ranged between zero and six caffeine-
containing drinks per day. The exposure assessment was
problematic and therefore the weak association with
weight reduction is of little value.
Grosso et al. (2001): There were over two thousand
pregnant participants in this cohort study of IUGR. Cord
blood samples were obtained for the analysis of caffeine
metabolites from 1,606 participants. Pregnancy symp-
toms were not evaluated. The investigators measured
cord serum caffeine, paraxanthine, theophylline, and
theobromine concentrations as indicators of the amount
of caffeine or its metabolites entering fetal circulation
after crossing the placenta. There was no association
between IUGR and caffeine intake during the first
(OR5 0.91; 95% CI5 0.44–1.90) or seventh month of
pregnancy (OR5 1.00; 95% CI5 0.37–2.70).
Grosso et al. (2006): The pregnancy signal was not
included in their evaluation. Women in the lower caffeine
exposure group delivered newborns with a reduced risk
of IUGR. Women with the highest concentrations of
paraxanthine had an increased risk of IUGR (OR5 3.3;
95% CI5 1.2–9.2). Fast metabolizers of caffeine and
caffeine metabolic products were associated with an
increased risk for IUGR (OR5 1.21; 95% CI5 1.07–1.37).
The fast metabolizers should have the lowest caffeine
levels and therefore, the lowest risk. This result is the
opposite of what one would have predicted, which
confuses the attempt to clarify the relationship of caffeine
exposure and the risk of fetal weight reduction.
Infante-Rivard (2007): There were 451 cases and 451
controls born after the 24th week of gestation with no
CMs in this SGA (10th percentile of less) case–control
study that examined the association of caffeine exposure
and the risk of fetal weight reduction. There were two
exposure groups (o300 mg/day vs. Z300 mg/day).
Maternal and newborn blood samples were obtained
for CYP1A2 and CYP2E1 polymorphisms genotyping.
Growth retardation was not affected by the polymorph-
ism in the mother or child. There was a very small
reduction in birth weight associated with an increasing
caffeine exposure in both the first and third trimester. For
every 100 mg of caffeine consumed, the birth weight was
reduced by 31 and 38 g for every 100 mg of caffeine
consumed during the second and third trimester,
respectively. These are very small reductions in newborn
weights and of no clinical significance whether or not
this is a causal association.
Klebanoff et al. (2002): This study measured para-
xanthine, the major metabolite of caffeine, in third
trimester serum samples banked for 2,515 women
participating in the Collaborative Perinatal Project
(CPP) between 1959 and 1966. Controls were selected
from the CPP population (Klebanoff et al., 1999). SGA
was defined as birth weighto10th percentile. The risk of
delivering a SGA infant increased with rising serum
paraxanthine concentrations, but only among smokers.
Increased risk among smokers was modest (ORE2.0 and
lower) and only present for categories of paraxanthine
concentrations exceeding 715 ng/ml. Apparently, there
were no associations with serum caffeine concentrations.
The pregnancy symptoms were not included in the
evaluation, which detracts from the validity of the final
analysis.
Ørskou et al. (2003): This study determined risk factors
for high birth weight (44,000 g). In a large prospective
cohort study, pregnant women were selected from a
cohort of over 24,000 pregnant Danish women who were
interviewed at approximately 16 weeks of gestation for
the average daily consumption of cups of coffee, tea,
cola, and cocoa, that was converted to total caffeine
intake (mg/day). The women who consumed more than
200 mg/day of caffeine were associated with a decreased
risk of giving birth to a high birth weight infant
(44,000 g). This study is not directly related to the
concern regarding the risk of caffeine producing new-
borns with SGA.
Parazzini et al. (2005) selected 555 women delivering
singleton, small for gestational age (SGA o10th percen-
tile) babies and 1,966 controls who delivered healthy,
term singletons for a case–control study. Caffeine
consumption was listed as the number of cups per day
before pregnancy and during each trimester. The
pregnancy signal data were collected on 50% of the cases
and 66% of the controls. The authors observed no
associations between SGA and intake of three or more
cups of coffee per day during pregnancy or 44 cups of
coffee per day before becoming pregnant.
Santos et al. (2005): This retrospective cohort study of
5,189 singletons was evaluated for SGA from exposure to
a caffeinated beverage consumed in South America
called mate´. All the mothers were interviewed within
the 24 hr following delivery. The investigators estimated
that the daily mate´ consumption was equivalent to a
daily average caffeine intake of 300 mg (Santos et al.,
1998). The investigators controlled for eight confounding
factors and concluded that mate (300 mg/day) does not
increase the risk of having a SGA newborn.
Tsubouchi et al. (2006): This study is a physiological
study of 10 pregnant women designed to measure
whether caffeine affects maternal and fetal blood flow
velocity using Doppler sonography. The pregnant wo-
men were given one cup of coffee (100 mg of caffeine)
before determining maternal and fetal blood flow in the
third trimester. The caffeine had no effect on blood flow
in the uterine artery, fetal middle cerebral artery, or
umbilical artery. This study only indicates that if fetal
growth retardation is caused by exposure to caffeine, the
mechanism is not via altering the blood supply to the
fetus.
Vik et al. (2003): Caucasian pregnant women who were
described as high risk based on their pregnancy histories
were selected before the 20th week of gestation to
participate in a caffeine exposure study. The high risk
category included the following criteria:
1. Low birth weight,
2. Smoking,
3. Prepregnancy weight o50 kg,
4. Previous perinatal death and being chronically ill.
A complete dietary analysis was performed for each
woman during various stages of pregnancy for 858
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women. The mean caffeine intake at the 17th week was
232 and 205 mg/day at 33 weeks. For a 60 kg woman the
caffeine exposure is 3.9 and 3.4 mg/kg, respectively. No
association was observed between ‘‘high’’ caffeine intake
at 17 weeks and giving birth to a SGA infant (OR5 1.1;
95% CI5 0.6–2.1), but high consumption at 33 weeks was
associated with an increased OR for SGA (OR5 1.6; 95%
CI5 1.0–2.5). Yet the findings in this study indicate that
high caffeine intake did not result in an increased risk of
newborns with SGA with caffeine exposures at mid-
gestation (17 weeks). The 33-week group exposed to high
exposures of caffeine did have a statistically increased
risk for infants with SGA.
Xue et al. (2008): The Mothers of subjects in the Nurses’
Health Study (n5 34,063) were sent questionnaires to
collect pregnancy and newborn data that occurred many
years in the past. The mothers answered a questionnaire
pertaining to events that occurred 40 to 60 years ago with
regard to caffeine ingestion. This is an exceptionally long
period of time to expect an accurate recall of the mother’s
caffeine ingestion. It is a serious deficiency in this study.
There were five categories of caffeine consumption
corresponding to never, o1, 1 to 2, 3 to 4, and Z5 cups
per day. The authors report that birth weight was
negatively associated with coffee consumption during
pregnancy decreasing by 15, 34, and 54 g for consump-
tion of 1 to 2, 3 to, 4 andZ5 cups of coffee per day during
pregnancy. These weight reductions are clinically insig-
nificant since it is one percent or less of the weight of a
newborn baby. Pregnancy symptoms were not consid-
ered as confounders.
Summary of the growth retardation stu-
dies. The growth retardation studies were not consis-
tent. In six of the studies the results were negative for an
association of growth retardation due to exposures to
caffeine. Seven of the studies were equivocal demon-
strating a risk for growth retardation with increasing
exposures to caffeine but with the inability to determine
the role of confounding factors. Four of the studies did
not evaluate the pregnancy signal. Two of the studies
were not devoted to the caffeine exposure and the risk of
fetal growth retardation. In some of the positive studies,
the magnitude of the growth retardation was clinically
insignificant. None of the epidemiology studies exam-
ined the growth retardation studies in animals that
indicated pharmacokinetically that exposures had to be
significantly above even the highest caffeine exposures to
which pregnant women would be exposed to produce
fetal growth retardation.
ANIMAL REPRODUCTIVE, DEVELOPMENTAL
AND IN VITRO STUDIES DEALING WITH
EXPOSURES TO CAFFEINE
Reproductive and Developmental Toxicology
Review of the animal studies has revealed some
interesting as well as unexpected findings. None of the
results of the oral administration of caffeine indicated
that caffeine increased the risk of embryonic death. While
a few manuscripts reported research conducted in
consideration of US (FDA) or international (ICH) guide-
lines, most are conducted using inappropriate routes of
exposure (only a few are relevant to normal human
exposure). Most oral studies were conducted at toxic
levels, that is, those in excess of the 30 mg/kg/day NOEL
in rodents, and only a few of the studies are relevant to
normal human exposures (in general, it was not possible
to extrapolate nonclinical bolus oral exposures to human
exposures). The results of the review of all the papers are
outlined in Supplemental Table 1, and Tables 6–9. Not all
the mg/kg/day dosages are available (in some cases
these can only be estimated, because of the route used).
There is also inadequate information regarding concen-
trations, consumption, and animal body weights. Sup-
plemental Table 1 represents a summary of the recent
animal toxicology literature pertaining to caffeine.
Extrapolating the results of caffeine animal toxicology
studies for human risk assessment:
1. Parental (i.v, i.p., and s.c.) administration in animal
study makes it difficult to perform human risk
assessment. Even once a day oral intubation presents
difficulties in utilizing the animal toxicology results
for human risk assessment.
2. Without human serum and animal serum levels of caffeine
and its metabolites, risk assessment is problematic.
3. Most animal teratology studies exposed the animals to
caffeine at the appropriate stages for comparing risks
in the animal model with potential risks in the human.
4. Most human exposures were measured in cups of
coffee per day. However, it is difficult to define a cup
(1 cup5 8 fluid ounces); coffee makers measure in
5-ounce serving cups. A 10 cup coffee maker5 50
ounces (www.Starbucks.com), which by standard
measure5 80 ounces, a discrepancy of 30 ounces or
a 27.5% difference in intake. ‘‘Cup’’ was never defined
in the publications reviewed.
5. Few studies reference International Regulatory Guide-
lines for pharmaceutical development (e.g., ICH, EG,
or FDA guidelines). Very few studies were performed
in compliance with current regulatory guidelines.
Most studies cited various animal use guidelines
(specified animal treatment/handling guidelines).
A previous review (Christian and Brent, 2001) of the
developmental toxicology of caffeine in animals and
humans identified a No Effect Level (NOEL) of
approximately 30 mg/kg/day in rodents, the reproduc-
tive NOEL to be approximately 80 to 120 mg/kg/day
and the teratogenic NOEL as 80 to 100 mg/kg/day based
on the following studies (Knoche and Konig, 1964; Palm
et al., 1978; Aeschbbacher et al., 1980; Nolen, 1981;
Nagasawa and Sakurai, 1986; Pollard et al., 1987; Purves
and Sullivan, 1993). The 2001 publication essentially
addressed the question of human teratogenicity of
caffeine. The publication cautioned that although preg-
nant women who do not smoke or drink alcohol and who
consume moderate amounts of caffeine (o5–6 mg/kg/
day spread throughout the day) do not have an increase
in any reproductive risks, individuals who consume
large amounts of caffeine are at greater risk of being a
smoker and of drinking alcoholic beverages to excess.
Such an individual may have an increased risk of
reproductive problems for other associated issues that
have not yet been recognized as important reproductive
and developmental toxic agents or behaviors.
If mammalian animal studies are to be utilized to
estimate human risks, the oral route is the only
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appropriate route for evaluating human risks from
exposure to caffeine in caffeinated beverages or naturally
containing caffeinated drinks, food, or medication. The
majority of animal caffeine studies did not use the oral
route. However, analyses of all animal studies were
performed regardless of the caffeine formulations,
vehicles, route of administration, doses, or stages of
pregnancy when exposure occurred. All recent animal
toxicology publications were reviewed for relevance.
Only those that included treatment during pregnancy, or
the early postnatal period in rats, when the brain is
similar in development to that of human fetuses, are
included in this review. These publications are included
by species and publication date in Supplemental Table 1,
and Tables 6 and 7.
Unfortunately, the better designed and more compre-
hensive animal studies were performed before 2000.
Palm et al. (1978) exposed Sprague–Dawley female rats
before pregnancy and throughout pregnancy to 12.5, 25,
or 50% brewed coffee in their drinking water, which was
equivalent to 9, 19, or 38 mg/kg/day of caffeine. Even at
the highest exposure there was no difference in the
number of resorptions, litter size, fetal weight of sex
ratio, or the offspring when compared to the control
litters. On the 38th post partum day the animals that had
been allowed to litter were comparable to the controls
with regard to litter size, viable young, birth weight, and
pup weight at 38 days. These results were in agreement
with other investigators (Aeschbbacher et al., 1980;
Nagasawa and Sakurai, 1986). Even relatively high
Table 8
Comparing the Pharmacokinetics and Toxicokinetics of Caffeine in Humans and Animals
Method of administration Exposure Plasma caffeine level Teratogenic effect
1 to 2 cups of coffee/day in humans; 1
to 2 mg/kg
100 to 200 mg of
caffeine
1 to 3mg/ml peak level Not teratogenic
3–5 cups of coffee/day in humans; 3
to 5 mg/kg
500 to 600 mg of
caffeine
5 to 6mg/ml peak level Not teratogenic
10 cups of coffee per day over a 10-hr
period
o1,000 to 1,200 mg of
coffee
Speculation; o10 mg/ml
peak level
Minimal data; unlikely to be
teratogenic
Caffeine in the drinking water in the
rat
80 mg/kg/day 5.772.3 mg/kg/day Not teratogenic
Caffeine in the drinking water in the
rat
205 mg/kg/day Peak ? Not teratogenic
Caffeine by once a day gavage in the
rat
80 mg/kg/day Peak 460 mg/ml Teratogenic
Caffeine in the drinking water in the
rat
330 mg/kg/day Peak 460 mg/ml Teratogenic
Caffeine in drinking water in the rat 80 mg/kg/day 0.10 to 5.74mg/ml Not teratogenic
Caffeine bolus of 25 mg, 24 hr later in
nonpregnant rat
25 mg/kg 2mmol/l 0.4mg/ml A pharmacokinetic study
Caffeine bolus of 25 mg, 24 hr later in
20-day pregnant rat
25 mg/kg 20mmol/l 4 mg/ml A pharmacokinetic study
Human exposure during pregnancy of
a mother who drank 9 to 24 cups of
coffee/day (Khanna and Somani,
1984; Bodineau et al., 2003)
900 to 2,400 mg/day
9 mg/kg to
24 mg/kg/day
80mg/ml at birth, estimated
40.3mg/ml at the 12th
postpartum day.
Maternal serum level on
the 10th postpartum day,
18.4mg/ml
No teratogennesis, growth
retardation. Liveborn who is
doing well and was weight-
appropriate for the
gestational age
Food and Drug Administration
recommendation (1980)
Limit caffeine to
o400 mg/day
(6.7 mg/kg/day
for a 60-kg
human)
Peak blood level will be
very low
No data; Very unlikely to be
teratogenic
Table 9
Mechanisms of Action of Environmental Teratogens
1. Cytotoxicity or mitotic delay beyond the recuperative capacity of the embryo or fetus (ionizing radiation, chemotherapeutic agents,
alcohol)
2. Inhibition of cell migration, differentiation, and cell communication
3. Interference with histogenesis by processes such as cell depletion, necrosis, calcification, or scarring
4. Biologic and pharmacological receptor-mediated developmental effects (i.e., etretinate, isotretinoin, retinol, sex steroids, streptomycin,
and thalidomide)
5. Metabolic inhibition (i.e., warfarin, anticonvulsants, and nutritional deficiencies)
6. Physical constraint, vascular disruption, inflammatory lesions, and amniotic band syndrome
7. Interference with nutritional support of the embryo by decreasing maternal food intake or affecting yolk sac or chorioplacental
function or transport
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exposures of caffeine or coffee in the water supply had
minimal effects on birth weight, pup weight, and
perinatal mortality in other studies (Knoche and Konig,
1964; Nolen, 1981; Pollard et al., 1987). Exposures of
caffeine up to 60 mg/kg/day in rats and 74 mg/kg /day
in mice did not alter the number of resorptions,
conceptions, litter size, or births (Aeschbbacher et al.,
1980; Nagasawa and Sakurai, 1986; Pollard et al., 1987).
The FDA commissioned an ‘‘in-house’’ study using
pregnant Osborne–Mendel rats that were administered
caffeine by gavage from 0 to 19 days of pregnancy with 0,
6, 12, 40, 80, or 125 mg/kg of caffeine with each
intubation (Collins et al., 1981). The highest dose was
maternally toxic as evidenced by the fact that 6 of the 50
pregnant rats in the 125mg/kg group died. CMs were
increased in the two groups with the highest exposure.
Ectrodactyly occurred in 28.5% of the fetuses in the
125 mg/kg group. The NOEL for CMs for caffeine was
determined to be 40mg/kg/day. Many investigators had
results that were similar to the FDA study (Bertrand
et al., 1965; Leuschner and Schverdtfeger, 1969; Bertrand
et al., 1970; Ikeda et al., 1982; Smith et al., 1987). It is
important to emphasize that gavage or tube installation
feeding will have a much lower teratogenic NOEL than
when caffeine is placed in the water or food supply. In
fact, in many studies investigators were unable to
produce CMs by adding large amounts of caffeine to
the water or food supply (Leuschner and Schverdtfeger,
1969; Gilbert and Pistey, 1973; Collins et al., 1983; Smith
et al., 1987). Some investigators were able to produce
malformations using caffeine in the water supply;
however, it required an exposure of 330 mg/kg/day
(Fuji and Nishimura, 1972).
Collins et al. (1981) demonstrated that a single oral
gavage exposure of 80 mg/kg of caffeine was teratogenic,
but 205 mg/kg/day in the water supply was not
teratogenic. Stillbirths and miscarriages were observed
with increased frequency among the offspring of
macaque monkeys treated during pregnancy with
caffeine in a dose equivalent to 5 to 7 or 12 to 17 cups
of coffee per day (Gilbert et al., 1988). The cause for the
stillbirths was not apparent at necropsy; no malforma-
tions were seen. Body weight of the male but not the
female infants of treated monkeys were reduced (Gilbert
and Rice, 1991).
An increased frequency of malformations, especially of
the limbs and palate, has been observed among the
offspring of rats or mice treated with caffeine during
pregnancy in doses equivalent to human consumption of
40 or more cups of coffee daily (Purves and Sulliva, 1993;
Nehlig and Debry, 1994). Fetal death, growth retardation,
and skeletal variations are often seen in these animal
experiments after maternal treatment with very high
doses of caffeine during pregnancy. In one study an
increased frequency of cleft palate was observed among
the offspring of rats given the equivalent of 19 cups of
coffee a day during pregnancy (Palm et al., 1978). An
increased rate of cardiac defects was observed among the
offspring of rats treated during pregnancy with the
equivalent of 15 or more cups of coffee per day in
another study (Matsuoka et al., 1987). Most investiga-
tions do not report an increased frequency of malforma-
tions among the offspring of rodents treated during
pregnancy with caffeine in similar or somewhat greater
doses (Purves and Sullivan, 1993; Nehlig and Debry,
1994; Christian and Brent, 2001). Doses and methods of
caffeine administration that are teratogenic in animal
studies generally cause maternal toxicity or death as
well, and equivalent human doses would also be highly
toxic or lethal.
Persistent behavioral and physiological alterations
have been observed in some studies among the offspring
of rats and mice treated during pregnancy with caffeine
in doses equivalent to 10 to 60 cups of coffee a day
(Nehlig and Debry, 1994). Behavioral alterations have
also been observed among the offspring of monkeys born
to mothers treated during pregnancy with caffeine in
doses equivalent to 5 to 15 cups of coffee per day (Rice
and Gilbert, 1990; Gilbert and Rice, 1994). The relevance
of these observations to the risks in infants born to
women who drink large amounts of caffeinated bev-
erages during pregnancy is unknown.
High doses of caffeine influence the teratogenic
activity of many other agents in animal studies (Nehlig
and Debry, 1994; Sivak, 1994). Co-administration of
caffeine often enhances the teratogenic action of other
agents, but in some instances there is no interaction and
in others, caffeine exhibits a protective effect. The
relevance of these findings to humans is uncertain.
There are animal experiments that do assist in the
evaluation of the human risks of caffeine exposure
during pregnancy (Tables 8 and 9).
Extrapolation of the Caffeine Animal Studies for
Human Risk Assessment (Supplemental Table 1,
and Tables 6–8)
Purves and Sullivan (1993) classified caffeine’s terato-
genic effect as a ‘‘peak blood level effect’’ and not an ‘‘area
under the curve effect.’’ This is important because it
emphasizes the importance of the method of administration
in designing animal studies that are designed to evaluate
the reproductive and developmental risks of caffeine in
human populations. The peak exposure plasma level in
animal models that is necessary to result in teratogenesis is
equal to or 460mg/ml (Elmazar et al., 1982; Ikeda et al.,
1982; Smith et al., 1987; Sullivan et al., 1987) (Table 10).
The results of properly planned animal studies can be
helpful in solving some of the dilemmas created by
inconsistent findings in epidemiological studies. An
animal study reported in 1960 first focused our attention
to the potential developmental effects of caffeine.
However, the exposure reported by Nishimura and
Nakai (1960) was from intraperitoneal injections of
250 mg/kg in the mouse, an extremely high dose that
would result in a blood plasma level that could never be
attained from consuming caffeine containing products in
food or beverages. More recent animal studies have
demonstrated that depending upon the method of
administration and species, the developmental NOEL
in rodents is approximately 30 mg/kg/day; the terato-
genic NOEL is 80 to 100 mg/kg/day, and the reproduc-
tive NOEL approximately 80 to 120 mg/kg/day (Nash
and Persaud, 1988; Nolen, 1989; Stavric, 1992; Dlugosz
and Bracken, 1992).
Purves and Sullivan (1993) agreed with the informa-
tion previously cited by the FDA, since their conclusions
are in basic agreement with the FDA position (1986).
However, Purves and Sullivan (1993) evaluated the
pharmacokinetics of caffeine more extensively, which is
important to estimate the risk. The cited studies and
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comments convincingly demonstrate that the route of
administration (bolus vs. administrating in drinking
water or diet) and the timing of treatment during
pregnancy (or development) are related to the serum
blood levels attained in the specific species tested. As a
result, this review indicates that such factors must be
considered in any risk assessment process for caffeine,
because under normal conditions of consumption, hu-
mans cannot attain serum blood levels comparable to
those associated with the threshold for adverse effects
from caffeine exposure in rats (Tables 8 and 9).
Although apparent differences exist because of the
duration of administration, the study by Collins et al.
(1983), in which caffeine was dissolved in drinking water,
and the previous study described by Nolen (1981), in
which caffeine was provided as brewed or instant coffee in
drinking water, have remarkable similarities in the mode
of caffeine administration (oral, drinking water) and the
effects produced. Both these studies were conducted using
adequate numbers of animals and well-defined protocols.
The relevance of the mode of exposure to resultant toxic
effects was also confirmed by Smith et al. (1987). In this
study Wistar rats were given 10 or 100 mg/kg/day of
caffeine on p.c.ds. 6 to 20, either as bolus oral doses (once
daily), or as four 2.5 or 25 mg/kg doses given at three-hour
intervals. Maternal body weight and feed consumption
were reduced in both groups given total doses of
100 mg/kg of caffeine and in the group given 25 mg/kg
of caffeine four times/day. Developmental effects in these
groups included dose-related decreases in fetal weight,
placental weight, crown-rump length and skeletal ossifica-
tion. Major abnormalities, principally ectrodactyly,
occurred only in the group given the bolus 100 mg/kg
dose, confirming the observations of Collins et al. (1983).
Colomina et al. (2001) exposed mice to caffeine
(30 mg/kg) and aspirin (ASA). (250 mg/kg by gavage
on the 9th post conception day.) There was no significant
maternal or developmental toxicity in this group of
animals and offspring. The studies also included stress-
ful restraint. However, the exposure and the stress in the
mouse studies cannot be utilized to determine human
developmental risks, especially since the developmental
results were minimal and the exposure equivalency in
the human is unknown.
Evereklioghi et al. (2003, 2004) administered caffeine i.p.
to Wistar rats on post conception days 9 to 21. There were
four groups: 0, 25, 50, and 100 mg/kg/day. There was no
maternal toxicity but there were seven fetal deaths in two
dams in the 100 mg/day group. The investigators attrib-
uted the embryonic deaths to the i.p. injections of a high
dose of caffeine. Histopathologic lens opacities were noted
in the 100 mg/kg group. The investigators were unable to
determine the human risk for cataracts from those studies.
Leon et al. (2002, 2005a,b) exposed Wistar rats to
caffeine in drinking water from day 2 until delivery. The
estimated exposure was 83.2 mg/kg/day. The authors
hypothesized that caffeine and theophylline could have
harmful effects on the developing fetal brain. Based on
their findings they hypothesized that caffeine and
theophylline may be associated with potentially harmful
effects on the developing fetal brain.
Lutz and Beck (2000) administered 1.0, 2.5, and
5.0 mg/kg of cadmium subcutaneously on post concep-
tion days 9 to 12 in C57 BL/6 JBK mice. They were
simultaneously administered zero or 50 mg/kg of caf-
feine subcutaneously. The teratogenic effects of cadmium
were ameliorated by the caffeine administration. Litter
size, fetal weight, fetal mortality, and dam weight were
not affected by the co-treatment of caffeine.
Saadani-Makki et al. (2004) exposed pregnant Sprague–
Dawley rats to 0.02% caffeine in their drinking water
(postconception days of exposure not mentioned). The
estimated caffeine consumption was 49.8 mg/kg/day. In
utero exposure resulted in an increase in birth rate. There
was also evidence for involvement of adrenergic A1
systems by the occurrence of respiratory perturbation in
newborns. There was no discussion of human risk
assessment of caffeine exposure based on these studies.
The critique of the animal studies may appear to
negate their usefulness in estimating human reproduc-
tive and developmental risks. This conclusion may be
due to the many animal studies utilizing parenteral or
bolus administration of caffeine. The smaller percentage
of animal studies that utilized the administration of
caffeine in the food or drinking water has yielded
important information summarized in Table 10. It
indicates that the NOEL for teratogenesis necessitates a
plasma level of caffeine 460mg/ml. This is unattainable
without pregnant women ingesting large quantities of
caffeine. For example, 10 cups of coffee over a period of 8
to 10 hr (1,000 mg of caffeine) would never be able to
reach a plasma level of 60mg/ml.
PHARMACOKINETICS
Cross-Species Similarities in Metabolism
One reason that animal models are useful in the study
of caffeine is that the pharmacokinetics of caffeine may
be similar to humans in some animal species. In both
animals and humans, oral administration of caffeine
results in its rapid absorption, with peak plasma levels
attained within 3 to 120 min (Perves and Sullivan, 1993).
The absorption rates also increase with increased dosages
in both humans and animals, and there is no significant
first-pass effect, although absorption and the intestinal
milieu do affect absorption, differing slightly in timing of
distribution, but otherwise comparable in attained blood
levels. Tomimatsu et al. (2007) described caffeine as
hydrophobic and rapidly passing through all biological
membranes, including the blood–brain and placental
barriers in sheep. Absorption from the gastrointestinal
Table 10
Magnitude of Congenital Malformation, Spontaneous
Abortion and Growth Retardation Risks From Exposure
to Caffeine During Pregnancy
Effect Risk Quality of the data
Congenital malformations Unlikely Good
Spontaneous abortion Minimal Fair to good
Fetal growth retardation Unlikely Fair to good
Conclusion: Consumption of caffeinated beverages during
pregnancy is unlikely to increase the risk of congenital
malformations and growth retardation; and poses a minimal
risk for miscarriage, possibly at very, very high caffeine
exposures. These risk estimates include the evaluation of
inconsistent epidemiology studies and the utilization of animal
(mammalian) reproductive studies.
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tract is rapid in adult humans, with attainment of
maximum caffeine concentrations within 15 to 60 min
after oral ingestion (for dosages of 5 to 8 mg/kg, the
plasma concentrations equaling 8 to 10 mg/ml) Supple-
mental Table 8. Once absorption occurs, caffeine is
rapidly distributed in body water, equilibrating between
blood and tissues, including the embryo/fetus, as well as
the brain and testes. It is also rapidly distributed to the
breast milk. Caffeine in human breast milk contains
approximately 75% of the plasma level, depending upon
the maternal dosage (3.2–8.6 mg/ml of caffeine is found in
human breast milk and 0.7–7.0 mg/ml in rat milk).
Consumption of caffeine in the milk results in only 1%
of the maternal intake being consumed by human infants
and 2% of the maternal intake consumed by rat pups
(Perves and Sullivan, 1993).
Pregnancy alters the metabolism of caffeine, which,
under normal conditions, is rapidly metabolically elimi-
nated. Caffeine’s retention is increased during pregnancy
in humans, late human fetuses, and neonates, with a half-
life varying from 80 to 100 hr. Presumably this increase in
retention is the result of deficient P-450 enzymes in the
fetus and neonate. Human metabolism of caffeine reaches
adult parameters after approximately 7 months of age, but
the half-life can be affected by inducing agents. For
example, the half-life in smokers is approximately half of
that in nonsmokers (Christian and Brent, 2001).
The characterization of the enzymatic process of
caffeine metabolism was also explored by Buters et al.
(1996), who investigated the involvement of CYP1A2
metabolizing enzymes in the pharmacokinetics and
metabolism of caffeine using mice lacking its expression
(CYP1A2/). The mice were intraperitoneally adminis-
tered 2 mg/kg of caffeine, a dosage that was reported to
be equivalent to that of a human drinking one cup of
coffee. The half-life of caffeine elimination from blood was
seven times longer, AUC was increased eight times, and
clearance was consequently eight times longer in these
animals than in wild-type mice. Other P450 enzymes were
not affected and the clinical pathology evaluations of the
liver and kidney were unaffected. These data indicate that
the clearance (elimination) of caffeine in wild-type mice is
primarily determined by CYP1A2. Because human and
mouse CYP1A2 resemble each other in cDNA-derived
amino acid sequence, these data also suggest that humans
have a similar elimination pattern.
Derkenne et al. (2005) confirmed the conclusions of
previous investigators that mouse or human CYP1A2 is
the predominant enzyme for theophylline metabolism.
Seven blood samples were taken at intervals from 5 to
400 min after IP injection of 8 mg/kg theophylline in
mice. Replacing mouse CYP1A2 (/) with a functional
human CYP1A2 gene restored the ability to metabolize
theophylline, and the metabolism changed to a human
profile. Comparing the hCYP1A1_A2 Cyp1a2 (/) and
wild-type mice with published clinical studies revealed
that theophylline clearance to be approximately 5 and
12 , respectively, greater than that reported in humans,
which is due to the well-known fact that mice clear drugs
more rapidly than humans. Metabolism of caffeine varies
remarkably among species and within the same species,
and it is highly dependent on variables such as sex, age,
and pregnancy status. In human newborns, the plasma
half-life of caffeine is 4 days, while in young children and
teenagers (6–13 years old), the plasma half-life is 2.3 hr.
In adult humans, the half-life averages 2-6 hr in healthy
nonsmokers, but it is prolonged in pregnant women to 10
to 20 hr. In rats, a half-life of 2.12 hr is reported for
8-week-old Sprague–Dawley male rats given one oral
dosage of 4 mg/kg of caffeine. The major metabolite in
humans is paraxanthine, or 1,7-dimethylxanthine. In rats,
the major metabolite is 1, 3, 7-diaminouracil, or 6-amino-
5-[N-formylmethylaminol]-1,3-dimethyluracil. Caffeine
is demethylated in both rats and humans to three
dimethylxanthenes (theophylline, theobromine, and
paraxanthine), which suggests that rats are an appro-
priate model for use in risk assessment for humans.
The differences in caffeine and paraxanthine metabo-
lism between human and murine CYP1A2 in liver
microsomes were also explored by Labedzki et al.
(2002). Results of the in vitro studies confirmed the
important role of CYP1A2 in both murine and human
metabolism of caffeine, despite formation of 1, 3, 7-
trimethylurate as an in vitro ‘‘artifact’’ in both human
and murine microsomal preparations. Both human and
murine CYP1A2 enzymes have close similarities in the
primary metabolic steps of caffeine. However, para-
xanthine in vivo was not metabolized by murine CYP1A2
to a relevant extent, which is in contrast to the human
situation. Also, results of this study confirmed the
known reported inhibitory effects of the quinolones,
norfloxacin, and pefloxacin on human CYP1A2, while in
murine hepatic microsomes, quinolones did not exert an
inhibition of caffeine 3-demethylation. The authors
concluded that murine models are important for under-
standing the metabolism of xenobiotics in humans, but
that extrapolation of data may be inaccurate in certain
cases, such as in cases where compounds have low
affinity ligands to CYP1A2. Therefore, interspecies
comparison may be required before the use of mouse
models to predict toxicity and/or pharmacological
activity in humans. However, the metabolic patterns in
rats are more closely related to the human.
Effect of Caffeine on the Neonate
The capability to adequately metabolize xenobiotics
are greatly reduced in neonatal or premature infants and
animals due to an inadequately developed hepatic
enzyme system, and often it is difficult to determine
exact medicinal dosages during this age. In humans,
intravenous theophylline is frequently administered to
premature neonates during the first several days to
reduce apnea, although there has been little emphasis in
the literature on the pharmacokinetics in this segment of
the population. Two clinical trials on this subject are
presented below to describe some of the pharmacokinetic
parameters.
The clearance rate (CL) and volume of distribution (V)
of theophylline were studied by du Preez et al. (1999) in
105 apneic premature neonates (mean weight: 1.3 kg; age:
1.1 days) receiving intravenous loading dosages of 4 to
7.7 mg/kg aminophylline. Maintenance dosages ranged
from 1.4 to 6 mg/kg/day in 2 to 4 divided doses. Data
were analyzed using the nonlinear mixed effects model
(NONMEM), and a one-compartment model with first-
order elimination. The study differed from other cited
premature neonatal references in that it was conducted in
South Africa on all-black babies that had a 92% incidence
of respiratory distress syndrome, and the described PK
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related only to the first few postnatal days. Low CL
values were recorded (0.0084 and 0.056 l/hr/kg, respec-
tively, for babies with and without oxygen support),
while values ofZ0.012 l/hr/kg have been cited by other
investigators. As a result of the low CL, long half-lives
(54 and 76 hr, respectively, for babies with and without
oxygen support) were reported. The calculated value for
V was 0.63 l/kg. Variability in both CL and V were high,
and it was concluded that theophylline PK is highly
variable in neonates because physiologic parameters are
changing rapidly and theophylline clearance and urinary
metabolite patterns apparently do not reach stable adult
values until 55 weeks postconception.
Urinary output was also evaluated in 19 premature
infants aged 4.574.0 days before and after a 20-min
loading solution of aminophylline (6 mg/kg), which was
followed by a maintenance therapy of 2 mg/kg every
12 hr (Mazkereth et al., 1997). The infants had a mean
gestational age of 31.172.8 weeks and a birth weight of
14817454 g. Marked diuresis occurred immediately after
the loading dose, and the ratio of urinary output to water
intake increased from 0.5870.36 to 1.1970.65. Fractional
excretion of sodium and potassium increased, and
urinary calcium and uric acid excretion was also
enhanced. Tubular reabsorption of phosphorus was not
affected. These effects were no longer evident after 24 hr,
despite aminophylline maintenance therapy. The authors
concluded that the aminophylline acted directly on
tubular reabsorptive functions of the nephron. Neonatal
patients afflicted with hyperbilirubinemia may also gain
some benefit from a neonatal rat model that could be
used to evaluate new therapeutic agents for this disease.
Induction of cytochrome P450 1A (CYP1A) may be a
valuable therapeutic modality for reducing the hyperbi-
lirubinemia of infants with Crigler–Najjar syndrome type
I (CNS-I), a severe form of congenital jaundice. To
evaluate inducers of CYP1A, a novel assay was estab-
lished by Jorritsma et al. (2000), based on the comparison
of the type of urinary pattern of caffeine metabolites in
rats when 10 mg/kg of 1-Me-14C-caffeine is injected
intraperitoneally before and 48 hr after injection of a
potential CYP1A inducer, such as 5,6-benzoflavone
(BNF). The inducing effect of BNF on CYP1A activity
was confirmed by the urinary pattern of caffeine
metabolites in Wistar rats and was paralleled by a
decrease in plasma bilirubin in male jj Gunn rats.
It is interesting to note that in conjunction with the
above study, a selective and sensitive reverse-phase
liquid chromatographic method was developed by
Schrader et al. (1999) for the simultaneous analysis of
[1-methyl-14C] caffeine and its eight major radiolabel-led
metabolites in rat urine. Separation of the complex
mixture of metabolites was achieved by gradient elution
with a dual solvent system using an endcapped C18
reverse-phase column, which, in contrast to commonly
used C18 reverse-phase columns, also allows the separa-
tion of the two isomers of 6-amino-5-(N-formylmethyla-
mino)-1,3-dimethyluracil (1,3,7-DAU), a metabolite of
quantitative importance predominantly occurring in rats.
Impact of Various Factors on Altering
the Pharmacokinetics of Caffeine
The effect of gender on the pharmacokinetics of
caffeine (5 mg/kg, intravenously) was explored in 10
male and 10 female Holstein cattle during the ages 1, 2, 4,
6, 8, 12, and 18 months (Janus and Antoszek, 2000). The
findings were compared to the results in other species,
including humans. The volume of distribution (V)
decreased significantly with age, as it does in pigs and
humans; results were similar in males and females.
A steady, significant decrease in mean residence time
(MRT) also occurred in both sexes, although the MRT
was significantly shorter in females after 8 months of age.
Significant decreases over time also occur in dogs, pigs,
and humans because caffeine clearance depends princi-
pally on intrinsic hepatic clearance. Total plasma clear-
ance (Cl) of caffeine increased by nearly 100% between
the first and 18th month of life (from 0.80 to 1.55 ml/
min/kg in males; from 0.84 to 1.80 ml/min/kg in
females). Similar changes occur in dogs and humans;
the change is due to inadequate development of the
hepatic microsomal enzyme system in the neonatal
period. It was concluded that clear-cut sex differences
in MRT and Cl occurred in cattle over eight months in
age, the females being the more active metabolizers.
In a similar manner, Janus et al. (2001) investigated the
effects of short-term (4 days) starvation or water
deprivation on the pharmacokinetics of caffeine
(5 mg/kg, intravenously) in three groups of ten 24- to
25-day-old Holstein calves. An automated enzyme-
multiplied immunoassay technique was used to deter-
mine plasma caffeine concentration just before the
administration of caffeine and four days later at the
end of the deprivation period. Results from the caffeine
study indicated that four days of starvation or water
deprivation was associated with significant increases in
MRT and Total Plasma Clearance (Clt) of 20 to 30%.
V was slightly (not significantly) decreased. It was
concluded that the results from this study were similar
to the findings reported in sheep, horses, laboratory
animals, and humans, and indicate that starvation and
water deprivation lead to a general inhibition of the
hepatic P450 enzyme system and may impair the elimina-
tion of drugs that undergo metabolism by these enzymes.
Pelissier-Alicot et al. (2002) investigated the effects of
caffeine on the daily rhythms of heart rate, body
temperature, locomotor activity, and caffeine pharmacoki-
netics (PK) in 10-week-old male Wistar rats in relation to
time-of-day. The study was divided into three 7-day
phases: a control period, a treatment period, and a recovery
period. During the treatment period, 25 mg/kg of caffeine
was administered subcutaneously to groups of rats (four
rats/group) at 8:00 AM in the morning, and to other groups
at 8:00 PM in the evening. Blood for PK parameters was
drawn at periodic intervals of 0.25 to 24 hr postinjection on
the 7th day of treatment. Telemetry was used in similarly
treated rats to obtain pharmacodynamics data. Morning
administration of caffeine suppressed locomotor activity
and modified the diastolic–systolic amplitudes of heart rate
and body temperature; evening administration did not
alter locomotion, but altered the blood pressure elevations,
amplitudes, and acrophases of the three rhythms, indicat-
ing a chronopharmacologic effect. PK data revealed that the
area-under-the-curve (AUC) was significantly lower in rats
medicated in the evening, compared to medication in the
morning, due to an increase in total plasma clearance and
volume of distribution. However, there was no significant
time of administration-dependent difference in Cmax, Tmax,
or half-life.
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The influence of hepatic regeneration after partial
hepatectomy (removal of median and lateral lobes) on
theophylline (Th) pharmacokinetics in groups of five
adult male Wistar rats was studied by Maza et al. (2001).
At 12 and 24 hr and 3, 6, and 15 days after partial
hepatectomy, Th was administered intravenously as a
single dosage of 6 mg/kg, and plasma concentrations
were determined at periodic intervals. Liver weights and
clinical pathology parameters were also determined.
Liver mass at the respective dates above were: 3.8, 5.0,
6.5, 7.1, and 9.4 g, compared to 12.1 g in nonhepatecto-
mized rats. Liver function tests were increased signifi-
cantly at 12 and 24 hr. Initial Th concentrations and
volume at steady state varied during regeneration. The
control elimination half-life of 4.3071.37 hr notably
increased after hepatectomy (7.2771.38 hr), and then
decreased with time to 5.1770.87 hr at 15 days. The
increase in elimination half-life led to a decrease in mean
residence time during the period of regeneration;
however, the intrinsic clearance hardly varied.
Appropriate Use of Animal Studies for Assessing
Human Risk
Although many metabolic and kinetic factors appear
similar in rats and humans, only clinical studies in
humans and intact animal pharmacokinetic studies in
animals can be used to extrapolate risks from animal
species to humans. There are few or no data regarding
blood levels attained or the comparability of dosages
administered. One of the most important considerations
regarding comparability of blood levels is that humans
consume caffeine over a period of time, rather than as a
bolus dosage, and certainly not from an intraperitoneal
injection. Humans consuming a 1 to 2 mg/kg dosage of
caffeine attain a blood concentration of 1 to 2mg/ml; a 3
to 5 mg/kg intake of caffeine results in a 5 mg/ml serum
concentration. Thus, a 1 mg/kg intake produces a
1 mg/ml blood concentration over the range humans are
likely to consume, fitting first-order kinetics for human
metabolism of caffeine. The kinetics in rats is dose-
dependent and zero order, indicating a saturable process,
particularly at high dosages (Christian and Brent, 2001)
(Tables 8 and 9).
Many animal studies in the previous review (Christian
and Brent, 2001) and in this current review were conducted
using bolus gavage dosages, rather than exposure over a
period of time as the result of administration in the
drinking water or diet. Such differences in the route of
exposure often confound interpretation of data and results
in inappropriate identification of the NOEL (no observable
effect level). Most comparisons are made on the basis of
mg/kg dosages, rather than attained blood levels, that are
generally considered more useful in cross-species extra-
polation, but which are rarely identified in human studies.
For example, pregnant rats that were administered caffeine
by gavage or via the drinking water for the first 11 days of
pregnancy and then administered an 80 mg/kg dosage of
radiolabeled caffeine on days 12 to 15 of gestation had
blood serum concentrations of caffeine that were much
greater after gavage dosage (60–63mg/ml) than after
drinking water exposure (0.10–5.74mg/ml). However, the
drinking water levels were more variable because of the
remarkable variability in timing and consumption of
drinking water. The half-life of an 80 mg/kg dosage of
caffeine in pregnant rats in this study was approximately
1.7 to 2.6 hr (Christian and Brent, 2001) (Tables 8 and 9).
When two bolus gavage dosage of caffeine, 5 and
25 mg/kg, were administered to Wistar pregnant rats,
apparent enzyme saturation resulted in nonlinear kinetics
at the higher dosage only, resulting in an increased half-life
and/or an increased distribution phase. However, mean
peak plasma concentrations in nonpregnant and pregnant
gestation day 20 rats and in the placenta, amniotic fluid,
and fetal blood were linear at approximately equivalent
times for both dosages. At 24 hr after the 25 mg/kg dosage,
plasma concentrations of caffeine were 2mmol/l
(0.4mg/ml) and 20mmol/l (4mg/ml) in nonpregnant and
pregnant rats, respectively, and the half-life was signifi-
cantly longer in pregnant (8.9 hr) than in nonpregnant
(3.8 hr) rats at the 5 mg/kg dosage but increased at the
25 mg/kg/day dosage, indicating saturation (Christian
and Brent, 2001) (Tables 8 and 9). When given intrave-
nously to pregnant sheep, as described by Tomimatsu et al.
(2007), maternal intravenous administration of 3.5 mg/kg
of caffeine resulted in a maternal plasma caffeine
concentration of 5mg/ml and fetal caffeine concentrations
in excess of 80% of maternal concentration. Other authors
cited that the metabolism of caffeine differs between rats
and humans, with the half-life much shorter in rats. Using
a correction factor, Tanaka et al. (1983) demonstrated that a
dosage of 70 mg/kg/day ingested by pregnant rats is
equivalent to a dosage of approximately 30 mg/kg/day for
humans. Thus, Bodineau et al. (2003) considered a 49 mg/
kg/day dosage of caffeine in drinking water to pregnant
rats to be in the moderate range for a human model
although all other authors consider this a high exposure.
Newborns exposed to caffeine in utero exhibited apnea
postnatally.
In toto, these toxicokinetic experiments show that
1. Serum and/or plasma concentrations of caffeine are
much higher in rats after gavage treatment than after
sipping treatment or continuous intravenous infusion;
2. Pregnancy alters pharmacokinetics in both humans
and rats, and
3. The changes may be dose-dependent and species-
specific.
Yet, pharmacokinetic studies with caffeine can serve a
very useful purpose, especially when it is used as a
biomarker for the estimation of xenobiotic biotransforma-
tion and possible hepatotoxicity. An example of such an
investigation was conducted in adult mice (BALB/c mice)
by Kolarovic et al. (1999). The test article was enflurane, a
fluorinated volatile anesthetic, administered by inhalation
in either anesthetic or subanesthetic doses, with/without
prior intraperitoneal injection of 1 g/kg ethanol. Two
control groups were administered only ethanol or saline.
Anesthetic exposure occurred for 6 hr/day for 5 days. On
the 6th day, half the mice were injected intraperitoneally
with 20 mg/kg caffeine and 8-hr urine samples were
collected for caffeine metabolite assay; remaining mice
were used to determine liver function and cytochrome
P450 analysis. Liver function tests were all normal, but
liver P450 levels were higher in the group treated with
enflurane and ethanol, compared to other groups. Excre-
tion of caffeine and its metabolites was different among the
groups. Quantities of caffeine metabolites that are pre-
dominantly metabolized by CYP-4502E1 were higher in
urine of enflurane-treated mice, while quantities of caffeine
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metabolites predominantly metabolized by CYP-4501A2
were significantly lower than in controls. Control values
for the CYP-4501A2 enzymes were: 1,7-dimethyl uric acid
(1,7-U)54.15571.956; 1,3,7-threemethyl uric acid (1,3,7-U)5
6.31472.992. It was concluded that use of caffeine as
a biomarker is a highly sensitive test for estimating
xenobiotic transformation and possible hepatotoxicity.
Plasma Levels Versus Organ Exposure
Plasma levels are not always indicative of exposure of
a specific organ. The disposition of caffeine and its
metabolites were evaluated in brains from adult and fetal
rats on p.c.d. 20 after a single maternal dosage of 5 or
25 mg/kg of caffeine. Fetal and adult caffeine AUC
values did not differ between brain and plasma at either
dosage. However, the three primary metabolites of
caffeine in rats accumulated in the fetal brain at
both dosages, resulting in a 3-fold increase in brain
metabolite exposure compared with fetal circulatory
levels (Christian and Brent, 2001).
Caffeine Studies Relevant to Teratogenicity or SA
(Pregnancy Loss)
Previous FDA (1980) conclusions and those described by
Christian and Brent (2001) appear to provide sufficient
precaution regarding consumption of caffeine, that is, that
moderate consumption of caffeine (which was defined as
r5–6 mg/kg/day) is unlikely to increase the risk of SA.
These conclusions also appear to apply to the two
additional human studies summarized below that were
included in the present literature search conducted in 2008.
In a case–control study of 73 women with, and 141
women without SA, Fenster et al. (1998) determined the
activity of the three principal caffeine-metabolizing
enzymes (P4501A2, xanthine oxidase, and N-acetyltrans-
ferase) by measuring the levels of caffeine metabolites in
urine. Caffeine was entered as a categorical variable in
models with the following levels of caffeine consump-
tion: no caffeine level; 1 to 150 mg/day (o2.5 mg/kg in
a 60-kg woman); and 4150 mg/day. Results established
no association between caffeine consumption, caffeine
metabolism, and risk of SA. However, due to small
sample size, the study was not able to reliably estimate
the risk for recurrent abortion in relation to caffeine
consumption and the indices of enzyme activity.
Possible adverse effects of caffeine on pregnancy were
also investigated by Klebanoff et al. (2002). They tested
2,515 women to determine whether third-trimester
maternal serum concentration of paraxanthine, caffeine’s
primary metabolite, is associated with the delivery of a
small-for-gestational age infant (birth weight of o10th
percentile for gender gestational age and ethnicity), and
whether the magnitude of the association is affected by
smoking. The subjects were selected from women who
enrolled in the Collaborative Perinatal Project at 12 sites
in the U.S.A. The mean serum paraxanthine concentra-
tion was greater in women who gave birth to small-for-
gestational age infants (754 ng/ml) than to ‘‘normally’’
grown infants (653 ng/ml, p5 0.02). However, the linear
trend for increasing serum paraxanthine concentration to
be associated with increasing risk of small-for-gestational
age birth was confined to women who also smoked
(p5 0.03). There was no association between para-
xanthine and fetal growth in nonsmokers (p5 0.48).
The Frog Embryo Teratogenesis Assay—Xenopus
(FETAX) was used to test the 13 metabolites, including
theophylline, paraxanthine, and a synthetic methyl-
xanthine analogue (Fort et al., 1998). Frog embryos were
exposed to two concentrations of each test article, with or
without a metabolic activation system. Assay results
indicated that the fetotoxic potencies of each of the
di- and monomethylxantine metabolites were similar to
that of caffeine. None of the caffeine metabolites tested
was found to be significantly more potent than caffeine
itself in the FETAX assay.
Modulation of Teratogenic Properties
of Other Agents
It is well known that low dosages of caffeine can
modulate the teratogenic effects of other agents in animal
studies. As summarized in Lutz and Beck (2000), defects
produced by ionizing radiation, chemical carcinogens,
and pharmaceuticals, including anticonvulsants, all have
been shown to be potentiated by nonteratogenic dosages
of caffeine. In contrast, 5-azacytidine-induced digital
defects in mice were suppressed by post-treatment with
caffeine. Treatment with caffeine also reduced the
teratogenicity of urethan, ethylnitrosourea, and 4-nitro-
quinoline-1-oxide. Although environmental exposures to
Cadmium (Cd) are not considered to be a human
teratogen, it has been shown to be teratogenic in rats,
hamsters, and mice, with the predominant malformation
being right-sided forelimb ectrodactyly in mice. This
malformation has also been reported in mice after
exposure to carbonic anhydrase inhibitors; acetazola-
mide, ethoxzolamide, and dichlorphenamide. The results
of a study by Lutz and Beck (2000) provide evidence that
a nonteratogenic dosage of caffeine (50 mg/kg, s.c.) can
ameliorate Cd-induced forelimb ectrodactyly in this
Cd-sensitive mouse strain (C57BL/6JBK mice) injected
intraperitoneally with 0, 1.00, 2.50, or 5.0 mg/kg of Cd on
post conception day 9 and examined on post conception
day 18 for ectrodactyly and other gross morphological
malformations.
Caffeine Interaction with Stress
A series of manuscripts were produced by researchers
at the University of Seville, Spain and the University of
Picardie Jules Verne, France (Bodineau et al., 2003;
Saadani-Makki et al., 2004; Gaytan et al., 2006) regarding
the potential effects of caffeine and other xyanthines
as the result of their binding with adenosine receptors
and their potential effect on respiration. Again, these
studies were conducted because caffeine is used ther-
apeutically to normalize breathing in apnea-affected
infants. The authors stated that premature infants may
be exposed to relatively high serum concentration of
caffeine (10–15mg/ml) for up to 8 weeks of treatment.
They referenced Shi et al. (1993) who demonstrated that
chronic caffeine exposure alters the density of adenosine,
adrenergic, cholinergic, GABA, and serotonin receptors
and calcium channels in the mouse brain, resulting in a
reduction in the fetal cerebral weight. They also indicate
that sustained maternal caffeine intake induces harmful
physiologic effects on human newborns, including
respiratory perturbations, citing a case report (Khanna
and Somani, 1984) of a woman reported to have
consumed 24 cups of coffee per day during pregnancy,
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with a newborn who experienced apnea episodes
attributed to methylxanthine withdrawal.
The first study by Bodineau et al. (2003) was
conducted using the drinking water route (calculated
consumed caffeine dosage5 4974 mg/kg/day). A sub-
sequent study by the same group (Saadani-Makki et al.,
2004) used tissues from the generated pups and
evaluated brainstem–spinal cord preparations isolated
from these newborn rats. In both studies, the authors
noted an increase in pup weight, without any considera-
tion for the mean number of pups per litter. Both these
observations should be considered unrelated to caffeine
[the increase in newborn weight (7.7 g) in the caffeine
exposed group versus the control (6.7 g) was most
probably the result of the fewer pups in the caffeine
group (10.9 pups) versus the control (13.8 pups), a
finding reflecting the relatively few litters evaluated
(eight per group) and the normal variability in litter
sizes]. No historical data were provided.
In the Bodineau et al. (2003) study, the consequences of
in utero caffeine exposure on respiratory output in
normoxic and hypoxic conditions and related changes
of Fos (binding protein involved in transcription regula-
tion) expression were evaluated. The study was con-
ducted using brainstem–spinal cord preparations
isolated from newborn rats. Sprague–Dawley rats (con-
trol and caffeine groups5 8/group) were given water or
0.02% caffeine in water, with intake evaluated daily,
presumably from conception until parturition, because
the caffeine was removed after parturition. The experi-
ments were conducted on brainstem–spinal cord pre-
parations isolated from 37 control and 35 caffeine group
rats. The authors claimed to know the exact dosage
consumed (50.4 ml/day control, 62.3 ml/day—caffeine)
with the consumption of 4974 mg/kg/day, estimated
according to drinking fluid intake. The body weight was
increased and litter size of the newborn caffeine group
rats was reduced, compared with the control group.
However, based on the standard deviation of the caffeine
group, it is probable that one litter was affected (data
were not provided; and the authors did not identify
statistical significance). A later study (Saadani-Makki
et al., 2004), using tissues from the same animals, further
evaluated involvement of the adenosinergic A1 systems
in the occurrence of respiratory changes in newborns
after in utero caffeine exposure and the importance of the
rostral pons in adenosinergic A1 modulation in respira-
tory control. As before, exposure was during pregnancy,
via maternal drinking water, and caffeine fluid intake
was estimated at 49.8 mg/kg/day, based on drinking
fluid intake, a toxic level. The authors concluded that
their work brought evidence of the involvement of the
adenosinergic A1 systems in the occurrence of apnea in
newborn infants after in utero caffeine exposure.
Further studies by this group (Gaytan et al., 2006)
evaluated postnatal exposure to caffeine on the pattern of
adenosine A1 receptor distribution in respiration-related
nuclei of the rat brainstem. They evaluated the ontogeny
of the adenosine A1 receptor system in the brainstem of
the newborn rat after postnatal treatment with caffeine.
This study identified that the previously reported results,
with the main difference between control and caffeine
administered rats being the transient increase (on
postnatal day 6 only) in the parabrachial and Ko˜lliker–
Fuse nuclei, which are classically associated with the
adenosine A1 receptor system. The authors concluded
that the role of caffeine in decreasing the incidence of
neonatal respiratory disturbances may be due to earlier
than normal development of the adenosinergic system in
the brain.
There was another group of publications originating in
Spain regarding the potential interactions of caffeine and
stress during pregnancy in mice (Colomina et al., 2001;
Albina et al., 2002). In the manuscript by Colomina et al.
(2001), a single oral dosage of caffeine or aspirin on p.c.d
9 was given to mice orally exposed to toxic levels of
caffeine (30 mg/kg/day), aspirin (250 mg/kg), or a
combination of caffeine and aspirin (30 and 250 mg/kg,
respectively). Three additional groups were given the
same doses and restrained for 14 hr. The pregnant mice
were restrained 2 hr/day on p.c.ds 0 to 18 by placing
them in methacrylate cylindrical holders and keeping
them in a prone position with the paws immobilized
with elastic adhesive tape, a procedure the authors
previously reported to produce stress in pregnant mice
(Colomina et al., 1995; Scialli et al., 1995; Colomina et al.,
1999). Other mice were given toxic dosages of caffeine by
gavage at 30, 60, and 120 mg/kg/day on GDs 0 to 18, and
another group was administered the same dosages of
caffeine immediately followed by restraint stress for
2 hr/day on the same days (Colomina et al., 1999). No
caffeine levels were recorded. Although the authors do
not identify maternal toxicity, it is noteworthy that the
weekly intervals measured for body weights are inap-
propriate (drug treatments and restraint occurred on one
day; the intervals are evaluated for three or four days).
Maternal toxicity was evident, with reductions or frank
weight losses in body weight and feed consumption
measurements. Regarding caffeine, these effects were
most severe for the three groups of interest (restraint,
30 mg/kg caffeine and combined 30 mg/kg of caffeine
and 14 hr of restraint), on p.c.ds. 9 to 11. Of these three
groups, the effects were most severe for the combined
caffeine and stress group. The 30 mg/kg plus restraint
group also had an increase in postimplantation loss,
including dead fetuses and late resorptions. An increase
in early resorptions was seen in the restraint alone group,
but the group with both restraint and 30 mg/kg of
caffeine were increased compared with the restraint
alone group. As would be expected, there was an
increase in reduced ossification in the restraint group
alone, the 30 mg/kg caffeine alone, and the combined
caffeine and stress group. There was no increase in
malformations in any group. The authors considered
there to be some clinical relevance for the data because
real life involves multiple simultaneous exposure to
many chemicals. However, the duration of oral exposure
to aspirin and caffeine on gestational day 9 in this study
is not analogous to the type of stress experienced by
pregnant women who drink coffee and take aspirin.
Interspecies differences and pharmacokinetics and bioa-
vailability are both important consideration.
Albina et al. (2002) reported a study by Nehling and
Debry (1994) in which daily consumption of caffeine
ranged from 203 to 283 mg, or 2.7 to 4.0 mg/kg/day of
caffeine in adults (equivalent to 3.38–4.72 mg/kg for a
60 kg person). Albina et al. (2002) also refer to the FDA
1980 recommendation that pregnant women limit caf-
feine consumption to less than 400 mg/day (6.7 mg/kg/
day for a 60 kg human), based on animal studies (FDA,
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1980). These authors report that 30 mg/kg/day of
caffeine administered with maternal stress is an effect
level (they did not report that stress alone was an effect
level). Nonetheless, the authors recommended that
women under notable stress during pregnancy should
reduce caffeine ingestion to reasonable levels; for
example, a dosage of 10 mg/kg/day. For 60-kg women,
10 mg/kg/day would be a daily ingestion of 600 mg, or
four cups of strong coffee or eight cups of weak coffee.
Interaction of Caffeine as a Pharmaceutical
A series of studies in rats was conducted by Burdan
and his colleagues at the Experimental Teratology Unit of
the Human Anatomy Department of the Medical Uni-
versity School in Lublin, Poland. The initial objective was
to evaluate the effects of caffeine on skeletal develop-
ment, when administered by gavage during gestation
(Burdan et al., 2000). The later studies were designed to
evaluate the effects of over-the-counter preparations of
various mixtures of propyphenazone, caffeine, and
paracetamol, with the purpose of determining liver
toxicity (Burdan et al., 2001) and the prenatal risk of
COX inhibitors administered with or without caffeine
(Burdan, 2002, 2003, 2004). The studies were conducted
in general conformance with evaluations performed for
testing pharmaceuticals, but used fewer rats than are
usually utilized in studies designed for regulatory use
(generally 15 per group, rather than the recommended
16–20 litters), an abbreviated treatment period p.c.ds. 8 to
14, rather than the current usual interval, gestation days
7 to 17. As a result, the exposure period differs by one
day from many studies published for regulatory use.
Nevertheless, the manuscripts are well documented and
easily interpreted. All the findings regarding caffeine’s
maternally and developmentally toxic dosages do not
indicate new concerns, even in combination with the
interacting medications.
Burdan et al. (2000) did not observe adverse maternal
or developmental effects at caffeine dosages up to
70 mg/kg administered on p.c.ds. 8 to 14, which is
unusual. The Burdan et al. (2001) study showed that
caffeine is toxic to the liver only at dosages greater than
those tested in this study (the highest dosage of caffeine
tested was 70 mg/kg/day), and when given for a
prolonged period. The dosages tested in this study were
mixtures prepared in 5:3:1 ratio (acetaminophen,
isopropylantipryine, and caffeine), with the caffeine
dosages at 0.7, 7, and 70 mg/kg/day. Although the
authors concluded that the administration of the mixture
to nonpregnant rats at the maximum dosage tested in this
study only slightly impaired liver function, hepatotoxic
effects were observed in pregnant female rats at the high
dosage. Thus, they also concluded that the pregnant rat’s
liver was more vulnerable than the nonpregnant rat’s to
the tested materials, although they cautioned that the
studies were difficult to extrapolate to human exposure.
The next series of studies of combined drugs in over-
the-counter products evaluated acetaminophen, isopro-
pylantipyrine, and caffeine (Burdan, 2002). There were 29
control rats and 15 to 19 per group in those administered
the caffeine mixture. Caffeine was given by gavage at 0.7,
7.0, or 70 mg/kg, in combination with the other drugs
(acetaminophen:isopropylantipyrine:caffeine 5:3:1 ratio
[A:I:C]). The authors concluded that this mixture of
acetaminophen, isopropylantipyrine, and caffeine admi-
nistered in a constant proportion of 5:3:1 for the entire
second week of pregnancy was not teratogenic in rats but
was maternally toxic at the mid and high dosages
(35:21.4:7 and 350:214:70 mg/kg, respectively), and was
embryotoxic only at the high dosage (350:214:70 mg/kg,
respectively).
Burdan (2003) then administered dosages of 3.5:0.7,
35.0:7.0, and 350:70 mg/kg/day of paracetamol:caffeine,
respectively, on p.c.ds. 8 to 14. All dosages were
maternally toxic, producing reduced maternal weight
gain and liver weight. The mid and high dosages also
reduced kidney weights, observations that were attribu-
table to paracetamol. At the maternally toxic mid and
high dosages, reduced fetal body weight/growth and
placental weight occurred, previously described rever-
sible effects of gavage dosages of caffeine, but there was
no increase in fetal malformations.
Finally, Burdan (2004) administered maternal dosages
of 2.1:0.7, 21:7, or 210:70 mg/kg prophyphenazone:caf-
feine on p.c.ds. 8 to 14. The only evidence of maternal
toxicity was decreased liver weight at the high dosage.
Fetal body weight was reduced in groups given the
middle (21:7 mg/kg prophyphenazone:caffeine) and
high (210:70 mg/kg prophyphenazone:caffeine) dosages
of the propyphenazone:caffeine mixtures and the middle
dosage of the propyphenazone:paracetamol mixture. The
effects on fetal body weight were not dose-dependent,
possibly because of the increase in resorption that also
occurred at the high dosage. These results are similar to
the previously described parallel studies in which all
three compounds were given separately or in a mixture.
Dose-dependent liver injury was seen in dams given
propyphenazone and caffeine and the mixture with all
three ingredients, with a hepatotoxic effect and decrease
in maternal body weight in the middle and high dosage
groups. The authors concluded that co-administration of
propyphenazone and caffeine or propyphenazone and
paracetamol caused growth retardation but no terato-
genic effects and that the results supported the prenatal
safety of low dosages of caffeine.
In Vitro Study on Placental Gene Expression
Nomura et al. (2004) studied whether caffeine alters
gene expressions in human cytotrophoblast-like cell line,
Be Wo, using cDNA microarray technology. Tissues were
obtained from pregnant rats fed a 20% protein diet or the
same 20% protein diet supplemented with caffeine
2 mg/100 g body weight (20 mg/kg) from day 1 (fertili-
zation) until day 20 of gestation, when the placentas were
removed by Caesarean-section. Placental blood flow
decrease has the potential to lead to intrauterine growth
retardation. The present findings demonstrated that
caffeine caused a decreased level of Bcl-2 expression in
a human trophoblast cell line and placentas removed
from caffeine-administered pregnant rats. The exposure
of 20 mg/kg is very high and it would be problematic to
apply these findings to human pregnancies.
Caffeine Studies Regarding Adenosine Receptor
Interaction and Adenosine Effects
As noted in some of the studies previously discussed,
caffeine interacts with the adenosine receptor, and it is
the most widely known adenosine receptor antagonist.
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The biochemical mechanism underlying the effects of
caffeine is the blockade of adenosine receptors, which is
an antagonist for adenosine modulation. Although
adenosine receptor interaction wth caffeine may not
result in teratogenicity, caffeine may affect neuronal
growth and neuron interconnections during gestation
and the neonatal period. It would be important to
determine the NOAEL for deleterious effects on neuronal
growth and neuron synapse formation.
Caffeine modulation of adenosine receptor and onto-
geny was tested in the following studies. Snyder (1984)
provided an extensive review of adenosine as a potential
mediator of the behavioral effects of xanthines, approxi-
mately 20 years after it was identified that phosphodies-
terase was an enzyme that degraded cyclic AMP
(Sutherland and Rall, 1958; Butcher and Sutherland,
1962; Salmi et al., 2007). According to Iglesias et al. (2006),
adenosine, a nucleoside, is widely distributed in the
peripheral and central nervous systems and acts through
G-protein coupled receptors. Four types of receptors
have been identified: A1, A2A, A2B, and A3. A1 and A3
receptors inhibit adenylyl cyclase activity through Gi
protein. A2A and A2B receptors act by stimulating
adenylyl cyclase activity through Gs protein. A1 and
A2A receptors have a greater affinity with adenosine and
are blockaded by caffeine. Adenosine, working through
the A1 receptors, inhibits glutamate release, thus acting
as a neuromodulator and neuroprotector. Snyder (1984)
also noted that phosphodiesterase was inhibited by the
xanthines, including caffeine and theophylline, and that
via this mechanism, xanthines could elevate cyclic AMP
levels. However, to substantially inhibit phosphodiester-
ase, millimolar concentrations of caffeine were required,
approximately 100 times the levels of caffeine found in
the human brain after ingestion of typical dosages in
humans. In addition, it was noted that some inhibitors of
phosphodiesterase were 100 to 1,000 times more potent
than caffeine but without behavioral effects.
Adenosine has many effects, including dilation of
blood vessels, especially in the coronary and cerebral
circulation, inhibition of platelet aggregation, and inhibi-
tion of hormone-induced lipolysis. It also has a variety of
actions on central neurons, usually inhibiting sponta-
neous neuronal firing (Phillis and Wu, 1981; Stone, 1981).
Adenosine inhibition of the release of excitatory neuro-
transmitters is the predominant presynaptic activity,
although postsynaptic effects are also present. Many
studies were conducted testing the hypothesis that in
utero exposure altered adenosine receptors and their
activities, including postnatal functional activity in the
brain and heart. All the studies appear to have been
performed at dosages that either were toxic, were
reversible in effect, or not sufficiently well documented
for use in human risk assessment.
The first biochemical analysis of adenosine receptor
activity was by Sattin and Rall (1970) who demonstrated
that adenosine can increase the accumulation of cyclic
AMP in brain slices without conversion of adenosine to
cyclic AMP, an action on extracellular receptors. The
effects of adenosine on the enzyme adenylate cyclase,
which synthesizes cyclic AMP, revealed two distinct
subtypes of adenosine receptors, designated A1 and A2
(van Calker et al., 1979; Burnstock and Brown, 1981;
Londos et al., 1981). Depending upon the system,
adenosine increases or decreases adenylate cyclase
activity, with the enhancing actions occurring at micro-
molar concentrations via A2 receptors. Nanomolar
concentrations of adenosine cause the A1 receptors to
inhibit adenylate cyclase activity. Marked sterospecific
effects of phenylisopropyladenosine (PIA) occurs at the
A1 receptors. L-PIA is remarkably more potent than
D-PIA, although the two isomers are relatively similar in
effect at the A2 receptors. Most xanthines have similar
potencies blocking both A1 and A2 receptors.
Direct binding studies have demonstrated that in all
species studied, adenosine receptors labeled with
[3H]DPX, a xanthine derivative, binding showed that
nanomolar potency was present for adenosine deriva-
tives and sterospecificity for PIA isomers. However,
binding studies identified heterogeneity of adenosine
receptors beyond the A1 and A2 distinction. Another
xanthine derivative (DPX) was about 250 times more
potent in competing for [3H]CHA sites in calf than in
guinea pig and human brain. As summarized by von
Borstel and Wurtman (1984), considerable evidence has
been accumulated that competitive antagonism at cell
surface adenosine receptors may be the most important
molecular action for methylxanthines, including caffeine.
Administration to animals can produce sedation, brady-
cardia, hypotension, hypothermia, and attenuation of the
response of the heart, vascular, and adipose tissue to
sympathetic stimulation and are generally opposite to
those produced by caffeine or theophylline alone.
Methylxanthines competitively antagonize these and
other adenosine actions at concentrations similar to those
found in plasma after consumption of one to three cups
of coffee (5–30 mM) (Rall, 1980).
A series of new manuscripts identified in this review
describe studies designed to evaluate the effect of
caffeine on adenosine receptor ontogeny. One group of
investigators (Ade´n et al., 2000) identified that adminis-
tration of caffeine at dosages resembling those consumed
by humans does not significantly influence the develop-
ment of receptors known or believed to be affected by
caffeine. The results, described below, in contrast to other
publications, indicate that caffeine can modify adenosine
receptors and/or behavior. However, it is unclear what
dosages were used or what postnatal blood levels of
caffeine were attained. Ade´n et al. (2000) reported that
maternal caffeine intake has minor effects on the
adenosine receptor ontogeny in the rat brain. Caffeine
was provided in the drinking water given to pregnant
rats, beginning on p.c.d. 2 and continuing throughout
gestation and postnatal life of the offspring. Although the
authors noted that only a low dosage of caffeine was
administered, estimated to be up to 3 cups of coffee/day,
or what a woman might drink during pregnancy, it must
be noted that mg/kg/day consumed dosages vary
throughout gestation and lactation. This is further
confounded by the pup’s consumption of the maternal
drinking water, which contained caffeine. They reported
that low-dosage caffeine-exposure during gestation and
postnatal life had minor effects on the development of
adenosine A1 and A21 receptors and GABAA receptors
in the rat brain.
Other studies were often designed to evaluate whether
caffeine affected excitotoxic brain lesions in mice,
because it is often given to human pre-term newborns.
Bahi et al. (2001) examined the effects of caffeine on
neonatal excitotoxic lesions of the periventricular white
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matter. This study was designed to mimic caffeine
exposure of human preterm infants in neonatal intensive
care units. Most of this study is inappropriate for
inclusion in this review because it addresses postnatal
evaluations, rather than in utero exposure. It has been
included because it had two sets of experiments, one
performed postnatally and the other with in utero
exposure, unfortunately by the intraperitoneal route
(5 mg/kg caffeine citrate administered IP to 3 pregnant
dams on p.c.ds. 8–18 and another group injected IP with
12.5 mg/kg caffeine on p.c.ds. 8–11). Although no
mechanism was shown, it appeared that caffeine had a
neuroprotective effect in mice.
An interaction study in knock-out mice was performed
by Bjo¨rklund et al. (2007) to investigate whether the
response of the adenosine receptor system to a low
perinatal exposure to methylmercury (MeHg) would be
altered by caffeine treatment or eliminated by genetic
modification (A1R and A2AR knock-out mice). Pregnant
mice were administered 1 mM MeHg and/or 0.3 g/l
caffeine (430 mg/kg) in the drinking water. The con-
sequences of MeHg toxicity during gestation and
lactation were reduced by adenosine A1 and A2a
receptor inactivation, either by genetic deletion or
treatment with their antagonist, caffeine. This work also
showed a protective effect of a high caffeine dosage of
(430 mg/kg/day).
In a 2008 study, da Silva et al. evaluated maternal
caffeine intake to determine whether it affected acet-
ylcholinesterase in the hippocampus of neonatal rats. The
control group was given tap water, and the caffeine
group given 1.0 g/l caffeine diluted in tap water.
Experiments were performed using 30 male and 30
female pups at 7, 14, and 21 days of age. Caffeine did not
change the age-dependent increase of acetylcholinester-
ase activity or the age-dependent decrease of acetylcho-
linesterase expression. However, it resulted in a 42%
increase in acetylcholinesterase activity, without chan-
ging the level of acetylcholinesterase mRNA transcripts
in 21-day-old rats. These results further demonstrate the
ability of maternal caffeine intake to interfere with
cholinergic neurotransmission during brain
development.
A series of studies conducted by investigators in Spain
considered the effects of down regulation of Adenosine
A1 receptors and other receptors in the brain and heart
that are affected by caffeine (Leo´n et al., 2002, 2005a,b;
Iglesias et al., 2006). They reported caffeine intake as
83.2 mg/kg/day (administered at 1 g/l in the drinking
water from p.c.ds. 2 throughout pregnancy [sperm5
gestation day 1]). The reported estimated dosage appears
to be correct, because a 250 g rat would consume at least
20 ml/day of drinking water, although this value is
somewhat low for a pregnant rat. These investigators
considered this dosage equivalent to approximately 80 to
180 mg caffeine in a cup of coffee, or consumption of one
cup of coffee by a pregnant woman. This calculation
appears inappropriate because 180 mg consumed by a
60-kg human would be equivalent to only 3 mg/kg/day,
much lower than the 83.2 mg/kg/day dosage consumed
by the rats.
In the Leo´n et al. (2002) publication, it was reported
that caffeine consumption during gestation caused
down-regulation of adenosine A1 receptors in both the
maternal and fetal brain. The later publications noted
that it also inhibited A1 receptor function in the maternal
rat brain and down regulation of metabotropic glutamate
receptors in the brain from both mothers and fetuses
(Leon et al., 2005a,b). The results of this study, evaluating
isolated rat heart membranes, immunodetection of
mGluR1, indicate down-regulation of different compo-
nents of the mGlur I/PLC pathway in the maternal and
fetal heart, and loss of receptor responsiveness in fetuses
that can alter the physiological function of the heart,
especially in fetal tissue mGluRs.
Iglesias et al. (2006) demonstrated that chronic intake
of caffeine during gestation in rats down regulates
metabotropic glutamate receptors in maternal and fetal
rat heart. While most of the studies involve the inter-
action of caffeine with adenosine receptors (Sutherland
and Rall, 1958; Butcher and Sutherland, 1962; Snyder,
1984; Iglesia et al., 2006) caffeine also interacts with
adrenergic, cholinergic, GABA, and serotonin receptors
as well as calcium channels (Shi et al., 1993).
Cardiovascular Effects
Keller et al. (2007) provided an excellent review of
cardiovascular development in which maternal exposure
to hypoxic and bioactive chemicals, for example, caffeine,
can rapidly impact embryonic/fetal cardiovascular func-
tion, growth, and outcome. No specific description of
caffeine exposure in animals or humans was provided.
A study by Asadifar et al. (2005), while not relevant to
toxicity produced as the result of in utero exposure of
pregnant rats to caffeine, addresses the interaction of
combined effects of caffeine and malnutrition on Cu
content in the neonatal rat heart.The results of this
study, in which neonates were administered a normal
diet with 20% protein, 20% protein supplemented with
caffeine (4 mg/100 g BW) or 6% protein diet (malnour-
ished) or 6% protein supplemented with caffeine (4 mg/
100 g BW) from birth to postnatal day 10 were surprising
and not what was expected. The caffeine level was
considered comparable to consumption of a heavy coffee
drinker, defined as 4 cups of coffee containing an average
of 100 mg of caffeine and an average body weight of
50 kg (400 mg/50 kg5 8 mg/kg). The results show that
malnutrition did not impair mitochondria, and that
although it was expected that caffeine exposure would
aggravate their Cu status, the results were the opposite of
the hypothesis. Caffeine exposure affected Cu status
more in the normally nourished animals than in the
malnourished animals, an apparent protective effect.
Momoi et al. (2008) further evaluated maternal and
embryonic cardiovascular function in CD-1 mice admi-
nistered 10 mg/kg/day caffeine subcutaneously on
p.c.ds. 9.5 to 18.5 of a 21-day pregnancy period (this
information appears in error, because mice have an
18-day pregnancy). Blood levels were not reported, so it
is not possible to extrapolate to human exposure,
although the authors considered the exposure to be
equivalent to modest daily maternal exposure. (It should
be noted that the caffeine was administered by injection
rather than by oral administration in the diet, so it is
unlikely that this exposure was comaparable to human
caffeine exposures.) No maternal toxicity or increase in
embryo resorption was observed. At p.c.d. 18.5, crown-
rump length, forelimb length, and wet body weight of
caffeine-treated embryos were smaller than the control
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embryos. The main findings of the study were reported
as: (1) modest daily maternal caffeine exposure altered
regional developing embryonic arterial blood flow and
induced intrauterine growth retardation without impact-
ing maternal CV function or weight gain; (2) caffeine at
peak maternal serum concentration transiently reduced
embryonic carotid arterial flow to a greater extent than
dorsal (and descending) aortic or umbilical arterial flow;
(3) maternal adenosine A2A receptor blockade repro-
duced the embryonic hemodynamic effects of maternal
caffeine exposure; and (4) adenosine A2A receptor gene
expression in the uterus and developing embryo were
down regulated by maternal caffeine exposure. The
authors considered the 10 mg/kg dosage of caffeine to
be a modest maternal caffeine dosage. They also stated
that maternal caffeine effects in a mouse model may not
reflect human effects, and concluded that modest daily
maternal caffeine exposure may have a negative effect on
embryonic CV function and overall embryonic growth,
possibly mediated by adenosine A2A receptor blockade.
Another study in near-term fetal sheep (Tomimatsu
et al., 2007) was performed to test the hypothesis that
maternal caffeine administration does not significantly
alter fetal cerebral oxygenation. The authors considered
the dosage comparable to one that may be consumed by
pregnant women in daily life. The pregnant ewes and
their fetuses were instrumented at post conception day
12573 (term B 145 days). A total of 800 mg of caffeine
citrate (400 mg of caffeine, reported as approximately
8 mg/kg, that is, equivalent to 2–3 cups of coffee) into the
maternal inferior vena cava over 30 min. Fetal arterial
and sagittal sinus blood samples and maternal arterial
samples were collected every 10 to 15 min and analyzed
for blood gases, hemoglobin concentration, oxyhemoglo-
bin saturation, and calculated O2 content. Maternal
parameters were unaffected. Fetal arterial blood gas
values at 5, 30, and 40 min after the 30-min maternal
infusion of caffeine were also not significantly affected.
However, sagittal sinus O2 content and oxyhemoglobin
saturation were significantly decreased in fetuses,
although neither fetal heart rate nor mean arterial blood
pressure were significantly changed. After 30 min of
maternal caffeine infusion, fetal LD-CBF decreased
slightly (7%). Fetal cortical PO2 decreased, and arterial
to sagittal sinus O2, content difference, cerebral fractional
O2 extraction, and CMRO each increased 20 to 30% above
baseline. Authors concluded that the results of their
study showed findings that would suggest a small
compromise in cerebral oxygenation occurred without
affecting overall fetal systemic oxygenation. Further
studies are needed to determine whether there are any
related clinical findings.
Encephalization
There is some evidence that caffeine accelerates
encephalization (development of the cerebral cortex).
A publication by Sahir et al. (2000) describes a potential
model for studying human holoprosencephaly. These
investigators confirmed their previous in vitro work
(Marret et al., 1997), describing effects of caffeine on early
encephalization. In this work, they evaluated i.p. dosages
of caffeine (12.5, 25, or 50 mg/kg) administered on p.c.ds.
8, 9, and 10 and then scored the embryos for encepha-
lization. Increased encephalization was noted on
embryonic day 10 at all caffeine dosages, as compared
with controls, and on embryonic day 9 at the 25 and
50 mg/kg/caffeine dosages. Normalization of brain
anatomy and histology was noted within a few days
after caffeine was discontinued, observations in agree-
ment with the plasticity of the developing brain. The
dosages tested were high and administered by an
inappropriate route (12.5–50 mg/kg/day, i.p.) compared
to human consumption (2.7–4 mg/kg/orally over a day).
The results do not appear to represent a concern for
humans, although the model may be useful for the
evaluation of telencephalic vesicle formation. A later
publication by this group of investigators (Sahir et al.,
2001) used similar methodology, i.p. injection once daily
of mice on p.c.ds. 8.5 to 10.5 with 25 mg/kg/day of
caffeine or either of one of two inhibitors of cAMP-
dependent protein kinase (PKA). The dams were subse-
quently killed on p.c.d. 10.5, and the embryos were
evaluated for histology and various tests for gene
expression and sequencing. As cited previously, embryos
treated with 25 mg/kg caffeine had significant accelera-
tion of telencephalic vesicle formation, compared with
control embryos. The authors concluded that the study
showed involvement of PKA activity in caffeine-induced
acceleration of encephalization, however, at relatively
high exposures.
Potential Model for the Production of Cataracts
Two publications (Evereklioglu et al., 2003, 2004)
reported results from the same set of rats. The Ever-
eklioglu et al. (2003) study was designed to identify
whether histopathology could reveal changes in the
neonatal rat cornea resulting from caffeine exposure
during pregnancy. The Evereklioglu et al. (2004) study
focuses on the examination of the crystalline lenses in
neonatal rats. Unfortunately, the study methodology was
not well reported, and some tabular errors are evident,
which preclude appropriate independent interpretation
of the results.
Wistar pregnant rats and the i.p. route were used to
treat a control and three dosage groups. As the result of
the use of a route that is inappropriate for extrapolation
to human exposure (i.p. dosages of 25, 50, and 100 mg/
kg/day were administered between p.c.ds. 9–21),
exposure relevant to human exposure comparisons
cannot be made. A fifth group was given caffeine via
gavage at a toxic dosage of 50 mg/kg/day. Dams
delivered normally (generally on p.c.ds 20–21). Half of
the newborn rats per litter were decapitated at postnatal
day 1, and the eyes were examined. The remaining litters
were raised with their biological mothers and sacrificed
and decapitated at postnatal day 30 for eye evaluation.
Pups were evaluated on postnatal days 1 or 30, and the
eyes enucleated for corneal histopathology. Although the
investigators refer to ‘‘pup’’ and ‘‘groups’’ and statistical
analysis of these, it is somewhat unclear how this
occurred because it appears that only one randomly
selected eye (right eye) was evaluated. Thus, it appears
that each litter and dosage group is represented by only
one pup and one eye at each time interval.
No maternal toxicity was reported; however, 7 pups
were reported as ‘‘miscarried’’ by 2 dams in 100 mg/kg/
day caffeine Group 4 (high dosage), because rats do not
generally abort but resorb their dead conceptuses. These
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‘‘late fetal deaths’’ were probably either a sequela of IP
injection and/or apparent premature delivery associated
with incorrect identification of the mating date. Pup
body weights were slightly decreased in all groups in a
dose-dependent pattern. It is unclear whether the
number of litters evaluated included the aborted litter
at birth, or whether these litters were included with those
with pups evaluated on postnatal day 30. Table 1 in the
Everekiloglu et al. (2003) publication appears to incor-
rectly report the number of pups per litter as the mean
number of pups per litter at birth. The authors concluded
dosages of 50 mg/kg/day and higher affected develop-
ment of the cornea, particularly postnatal at 100 mg/kg/
day. Interestingly, macroscopic changes were not ob-
served in any corneas on postnatal day 30.
In the later publication regarding effects in the same
rats (Everekilioglu et al., 2004), the ultimate objective was
to establish a model for the study of cataract develop-
ment, specifically, to investigate histologically the influ-
ence of maternal caffeine exposure during pregnancy on
the development of the crystalline lenses in neonatal rats.
In the control and 25 mg/kg/day dosage groups, both
slit-lamp biomicroscopic and histopathologic examina-
tion of the crystalline lenses revealed normal findings.
Histological examination of the 50 and 100 mg/kg/day
IP groups and the 50 mg/kg/day PO group had findings
suggesting cataractogenesis, including eosinophilic de-
generation, lens fiber cell swelling and liquefaction,
central lens fibers with retained nuclei, and prominent
epithelial cells lining the posterior lens capsule behind
the equator. Some lenses in the intraperitoneal 100 mg/
kg/day group had immature cataract on slit-lamp
biomicroscopic examination at postnatal day 30. The
authors concluded that excessive maternal caffeine
exposure during pregnancy had cataractogenic effects.
As previously reported, no macroscopic ocular abnorm-
alities were observed in control or experimental groups
at birth, and the i.p. administration of high doses of
caffeine prevents the ability to perform a valid risk
assessment in humans.
EVALUATION, DISCUSSION, AND RISK
ANALYSIS
The method of evaluation that has been utilized in past
publications (Brent, 1978; Shepard, 1986, 1994; Brent
1986a,b, 1995a,b, 1997, 1999, 2003, 2005; Brent and
Beckman, 1990; Christian and Brent, 2001) will be
utilized in this publication and is described in Table 1.
It consists of evaluating the (1) epidemiological studies,
(2) determining whether secular trend analysis is an
appropriate technique to utilize, (3) animal studies, (4)
evaluating the available pharmacokinetic and toxicoki-
netic information, (5) Testing the biological plausibility of
any reported findings or hypotheses based on (a) MOA
(mechanism of action), (b) receptor agonistic and
antagonistic effects, (c) enzymatic stimulation or sup-
pression, and (d) basic reproductive and developmental
teratology principles.
Epidemiological Studies
Epidemiological studies are the most important area of
research for evaluating human risks from environmental
exposures. It is most helpful if the epidemiology study
results are in agreement (consistent). We know that
cohort studies are the most likely to be accurate with
regard to identifying causal associations; however, for
rare events you need very large exposed populations
to study. They are costly and difficult because the studies
need large numbers of cases and controls. Case–control
studies can be performed with smaller numbers of
cases and controls and are more likely to find associa-
tions that are not causal. Consistent findings of increased
risks or no increased risks strengthen the believability of
the results. None of the new caffeine epidemiological
studies of the 21st Century included complete pharma-
cokinetic data in their research protocol. The studies
continued to measure exposure by cups per day, per
week, or even per month of caffeine containing bev-
erages. Some investigators hypothesized that slow
metabolizers of caffeine may be at greater risk because
the mother’s serum levels of caffeine and caffeine
metabolites would be higher and protracted. The studies
of CYP1A2 activity’s impact on the risk of SA were
inconsistent and in some cases the results were the
opposite of what was expected.
In this publication the epidemiological studies
pertaining to SA, CMS, and fetal growth retardation
were evaluated noting that appropriate animal studies
can assist in the risk assessment analysis.
SA. Of all the reproductive and developmental
events, SA is the most difficult to evaluate in epidemio-
logical studies (Tables 2 and 3). The complexity of
performing research involving the evaluation of whether
a particular environmental agent is responsible for an
increase in the prevalence of SA is discussed in detail in
the SA section of this article. Furthermore, it will be
obvious that many of the epidemiological studies failed
to recognize the impact of the factors that alter the
veracity of epidemiological studies dealing with SA,
which are summarized in the earlier section. Seventeen
caffeine epidemiological studies were reviewed that
were concerned with SA. Almost all the studies reported
no association in pregnant women consuming three or
less cups of coffee per day. Eight of the studies were
negative at all exposures that were studied. The
epidemiology studies were not consistent in their
conclusions. At high exposures it was difficult to
eliminate confounding factors such as smoking, alcohol
ingestion, decreased nutrition, the Susser effect, and
many other confounding factors that may be associated
with ‘‘excessive’’ caffeine ingestion. So the conclusion in
this review was that caffeine ingestion at the usual or
even very high exposures is an unlikely cause of SAs. Ten
of the studies did not account for the impact of the
‘‘pregnancy signal’’. Only one of the studies discussed
the multiple etiologies of abortion and the complexity of
performing SA research studies. Nor did these epide-
miology studies cite the animal studies that examined
embryonic and fetal resorptions that refuted the concept
that caffeine is an abortifacient at the usual or even high
exposures of caffeine in pregnant women.
Congenital malformations (CMs). Each of the 11
recent CM epidemiological studies evaluated only one
particular isolated birth defect and none of them focused
on a syndrome of abnormalities that is usually associated
with a teratogenic effect. Most teratogens do not produce
a single isolated defect. Teratogens produce an identifi-
able syndrome of effects that are caused by the teratogen
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(Wilson and Brent, 1981; Beckman and Brent, 1986a;
Brent, 1986b, 1994, 1995a,b, 1999, 2004, 2008; Shepard,
1986, 1994; Beckman et al., 1997; Cary et al., 2009)
(Table 5).
The congenital malformation studies dealing with
caffeine focused on the following individual malforma-
tions: cleft lip and palate, hypospadius, cardiac mal-
formations, Down syndrome, anorectal atresia, kidney
malformations, and cryptochidism. All were negative,
except for the Schmidt et al. (2009) study. The Schmidt
et al. (2009) study reported an association of caffeine
ingestion with isolated NTDs. This study had serious
errors and inconsistencies that are detailed in the earlier
section. However, the protocols of all these studies did
not utilize the basic principles of teratology in selecting
the malformations to study or in analyzing the results
(Table 5). It is clear from previous epidemiological
studies and the animal studies that caffeine does not
represent an increased teratogenic risk. Even much
higher exposures than 3 to 5 mg/kg/day are not
teratogenic. Depending upon the method of administra-
tion and the species, animal studies have demonstrated
that the developmental NOEL in rodents is approxi-
mately 30 mg/kg/day, the teratogenic NOEL is 80 to
100 mg/kg/day, and the reproductive NOEL approxi-
mately 80 to 120 mg/kg/day (Knoche and Konig, 1964;
Aeschbbacher et al., 1980; Nolen, 1981; Nagasawa and
Sakurai, 1986; Pollard et al., 1987; Purves and Sullivan,
1993).
The animal studies that utilized pharmacokinetics
estimated the teratogenic plasma NOEL at 60 mg/ml, a
level that would rarely, if ever, be reached from caffeine
nutritional exposures in pregnant women (Tables 8 and 9).
The malformations described in the animal studies at
very high doses fit the description of vascular disruptive
types of malformations (Nishimura and Nakai, 1960).
However, in the epidemiological studies reporting
malformations in a caffeine-exposed population, the
malformations that were selected for the study were
not of the vascular disruptive type and no caffeine
teratogenic syndrome has been described (Wilson and
Brent, 1981; Brent, 1986, 1994, 1999, 2004, 2008; Christian
and Brent, 2001).
Fetal weight reduction. The 17 epidemiology
studies dealing with the risk of fetal growth retardation
from caffeine exposure during pregnancy did not
consistently report that growth retardation was present
in these studies. Four of the studies reported growth
retardation with ingestions above 300 mg/day and eight
of the studies did not. In eight of the studies the
‘‘pregnancy signal’’ was not included in the evaluation.
The decrease in birth weight was very small and had
minimal clinical significance. In some of the positive
studies many of the possible confounding factors that
could be etiologically related to growth retardation
(tobacco, alcohol, nutritional problems, maternal disease
states, maternal behavioral, or psychiatric problems)
were not evaluated (Smith, 1947). While large doses of
caffeine administered parentally or by bolus to rats or
mice can result in fetal growth retardation, the studies
utilizing caffeine in drinking water or the food supply
(Aeschenbacher et al., 1980; Nagasawa and Sakurai, 1986;
Pollard et al., 1987) did not result in rat or mouse fetal
growth retardation at exposures that are much higher
than are likely to occur in the human.
None of the epidemiological studies focused on the
difference between reparable and nonreparable growth
retardation. Many causes of growth retardation are
permanent and the infant never recovers from the in
utero growth retardation (chromosome abnormalities, in
utero teratogenic and nonteratogenic infections, many
teratogenic drugs and chemicals and some forms of
nutritional deprivation). Reparable growth retardation
following placental insufficiency or from pregnancies
whose mothers smoked have much better prognosis than
the fetuses that never recover completely from the in
utero growth retardation. None of these studies deter-
mined whether the subjects in their studies recouped or
recovered from their decreased growth in utero.
Inconsistent findings of growth retardation and igo-
noring the importance of the pregnancy signal diminish
the value of the conclusions of the epidemiology studies.
Thus, fetal growth retardation is unlikely to be caused by
the usual human exposures of caffeine.
Secular Trend Analysis
When a significant segment of the population is
exposed to a drug or chemical, changes in population
exposure may be associated with an increase or decrease
in the incidence of reproductive or teratogenic effects.
This can happen when a very popular drug is introduced
or withdrawn from the market. Secular trend analysis
cannot be utilized if only a very small segment of
the population is exposed. Caffeine exposure is so
universal and difficult to monitor that it would be
impossible to attribute changes in reproductive or
developmental effects to changes in population caffeine
exposure.
Animal Developmental Toxicity Studies
(Supplemental Table 1, and Tables 6–9)
When human epidemiological studies or a case series
presumptively indicate that a cluster of malformations
may be caused by a drug or chemical, an animal model
may be developed that mimics the human developmen-
tal effect at clinically comparable exposures (Brent et al.,
1986). There are over 50 proven human teratogens and
for almost every teratogen scientists have been able to
produce an animal model at exposues pharmacokineti-
cally comparable to the human exposures (with the
exception of infectious teratogens that primarily affect
the human species) (Brent, 2004, 2008). Animal studies
have demonstrated that the developmental NOEL in
rodents is approximately 30 mg/kg/day; the teratogenic
NOEL is 80 to 100 mg/kg/day, and the reproductive
NOEL approximately 80 to 120 mg/kg/day (Persaud,
1988; Nolen, 1989; Nash and Stavric, 1992; Dlugosz and
Bracken, 1992). These NOELs are derived from caffeine
administration via bolus administration. The NOELs are
much higher when the caffeine is administered in the
food or water supply. Only eight (8) of the recent animal
studies administered the caffeine in the drinking water
or food. In those studies that estimated pregnancy loss,
there was not an increased risk of pregnancy loss with
exposures much higher than the 30 mg/kg. All the
animal studies that evaluated the risk of congenital
malformations found no increased risk with the usual or
even the highest range of human caffeine exposure
(Supplemental Table 1, and Tables 6–9). The smaller
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percentage of animal studies that utilized the adminis-
tration of caffeine in the food or drinking water has
yielded important information summarized in Table 10.
It indicates that the NOEL for teratogenesis necessitates a
plasma level of caffeine 460 mg/ml. This is unattainable
without pregnant women ingesting very large quantities
of caffeine. For example, 10 cups of coffee over a period
of 8–10 hr (1,000 mg of caffeine) would never be able to
reach a plasma level of 60mg/ml. This is true for growth
retardation and pregnancy loss as well.
Pharmacokinetics
Some of the animal studies performed before 2000
have provided investigators with pharmacokinetic data
that can be utilized for risk analysis (Knoche and Konig,
1964; Aeschbbacher et al., 1980; Nolen, 1981; Nagasawa
and Sakurai, 1986; Pollard et al., 1987; Perves and
Sullivan, 1993) (Table 10). One of the recommendations
of the Christian and Brent (2001) ‘‘Teratogen Update’’
was that any future caffeine epidemiological studies
should measure caffeine and caffeine metabolites as an
important component of the study. Extensive information
regarding the metabolism of caffeine is presented in this
publication. The information should be useful for future
investigations in the caffeine field, so that any future
caffeine toxicology studies will have a significant
pharmacokinetic component. The inconsistencies of
previous studies are partly the result of not knowing
the actual exposures of the participants. In Tables 8 and 9
are the animal and human pharmacokinetic data that are
available for human risk assessment. These tables are the
most important tables in this publication because they
demonstrate that it is unlikely that a pregnant woman
could ingest enough caffeine via her diet to result in fetal
growth retardation, pregnancy loss, or congenital
malformations.
Biological Plausibility (Biological Common
Sense)
Case reports and clusters. It is a common knowl-
edge (a truism) that most teratogens have been dis-
covered by an alert physician or scientist from clusters
of patients with a group of similar malformations
(Brent et al., 1986; Carey et al., 2009). An historical
example is Gregg’s observation of children in his
ophthalmology practice with cataracts and associated
malformations whose mothers had contracted Rubella
during their pregnancy (Gregg, 1941). Case–control
studies verified his observation as being correct. Another
teratological truism is that a single case report of a
drug exposure during pregnancy that resulted in a
malformed child is rarely a causal relationship. Is a
single case report ever useful? Bodineau et al. (2003) cited
a case report of a newborn ‘‘intoxicated’’ by caffeine
because the mother drank 24 cups of coffee/day during
pregnancy.
The case report reads as follows (Khanna and Somani,
1984):
A male infant weighing 1,236 g was born to a 23-year-
old Gravida 1, Para 0, white married woman at 27 weeks
gestation. Amniotic fluid was leaking for 24 hr before
delivery. The mother received 10% alcohol i.v. to attempt
to stop the labor without success. She also received 16 mg
of Dexamethasone i.v. 24 hr before delivery. The infant
was spontaneously delivered vaginally. Apgar scores
were 9 and 10. The infant developed respiratory distress
and was administered 40% oxygen before being referred
to a high-risk neonatal center. The gestational age was
estimated to be 31 weeks at the neonatal center. He was
diagnosed with transient tachypnia of the newborn.
Cultures and electrolytes and the metabolic panel were
all negative. Apnea of 420 sec was first noted at 4 days
of age. On the 5th day, because of the apnea and the
history of caffeine ingestion, a blood specimen was
obtained for caffeine followed by caffeine administration
(10 mg/kg), followed by 5 mg/kg every 12 hr. By the
sixth day the apnea was no longer present. The serum
caffeine concentration before the administration of
caffeine was 40.3 mg/ml. The half-life of caffeine in a
premature baby is estimated to be approximately 100 hr.
It was estimated that at birth the infant had an estimated
serum caffeine level of 80 mg/ml. On the 12th day
postpartum, the serum caffeine concentration in the
infant was 47.7 mg/ml.
No congenital malformations were detected and the
infant’s birth weight was normal for gestational age. No
further problems were encountered and the baby was
discharged at 43 days of age. A serum sample
was obtained from the infant at the time of discharge
and was 0.7 mg/ml. At the postdischarge follow-up at 6
months later, the child was growing and developing
normally.
The history of maternal caffeine intake is interesting.
During the pregnancy she was taking as much as 24 cups
of coffee per day. About 5 days before delivery, she
reduced her coffee at work to 5 to 6 cups of coffee per
day. After delivery she was drinking 5 to 6 cups of coffee
per day. A maternal serum caffeine level on the 10th
postpartum day was 18.4 mg/ml. Unfortunately, we do
not have a caffeine level when she was taking 24 cups of
coffee/day.
How much information can you obtain from one
clinical report? It is apparent that this case report is
extremely valuable. When a subject ingests 3 to 5 cups of
coffee/day, a 60-kg subject is exposed to 5 to 8 mg/kg,
which results in a serum concentration of 8 to 10 mg/ml.
These are not absolute figures. For example, Stavric
(1988) states that when a human consumes a cup of
coffee delivering a 1 to 2 mg/kg dosage of caffeine it
results in a blood concentration of 1 to 2mg/ml, while a 3
to 5 mg/kg intake leads to a 5mg/ml concentration. The
serum measurements in this case-report indicate that the
infant may have received a massive caffeine exposure as
a fetus. If the infant was exposed to a very high level of
caffeine why was the infant not growth retarded or
malformed? Most likely, because the caffeine levels did
not reach 60 mg/ml and lower levels do not produce
congenital malformations or growth retardation.
The importance of the ‘‘mechanism of action’’
(MOA). The evidence that demonstrates that an
environmental toxicant can produce reproductive or
developmental effects in humans can be determined
from the results of five areas of investigation (Table 1).
Dose–response relationships in the reviewed epidemiol-
ogy studies are primarily determined by estimates of
exposures and there is meager data pertaining to the
pharmacokinetics of caffeine and its metabolites. Since
2000, only four epidemiology studies reviewed in this
article considered actual exposures. Even more
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surprising is the fact that none of the epidemiological
studies discussed the mechanism by which caffeine can
produce SAs, congenital malformations, stillbirths, pre-
maturity, fetal growth retardation, or fertility problems.
The mechanisms by which reproductive toxicants pro-
duce their effects are listed in Table 10. Only one of the
listed mechanisms in Table 10 have the possibility of
providing a mechanism for reproductive toxicity of
caffeine and that is agonistic or antagonistic effect on
the adenosine, adrenergic, cholinergic GABA, or seroto-
nin receptors. The pharmacokinetic levels of caffeine
from low and high exposures are not cytotoxic or
mutagenic. Nor is there definite data indicating that it
can affect development or reproduction by any of the
other mechanisms listed in Table 10.
The importance of the ‘‘pregnancy signal’’. The
‘‘pregnancy signal phenomenon’’ has been discussed in
many obstetrical and epidemiology publications (Weigel
and Weigel, 1989; Lawson et al., 2004). In the Lawson
et al. study, the authors reported that the vast majority of
nonsmoking coffee drinkers decreased or quit drinking
coffee during the first trimester. In fact 65% reported a
unique aversion to coffee. There was a 59% decrease in
coffee consumption between the 4th and 6th week of
gestation. The authors were of the opinion that a decrease
in coffee consumption may be a signal for a healthy
pregnancy and therefore can act as a confounder. In many
of the epidemiological studies published between 2000
and 2010, including the SA studies, the pregnancy signal
was not considered. This omission could invalidate the
results and conclusions of these studies.
Fecundity and fertility studies. Preconception
exposure of sperm or ova (eggs) to mutagenic drugs and
chemicals have theoretical risks of producing chromo-
some abnormalities or point mutations in the developing
germ cells. Since caffeine is not a potent mutagen or
carcinogen, an increase in the mutagenic risks would
appear to be very unlikely (Table 10). There is extensive
evidence supporting the conclusion that even potent
mutagens at low exposures have a very low risk of
having a significant effect on the developing surviving
fetuses at term or a mutagenic effect (chromosomal
abnormalities and point mutations). At high exposures,
mutagenic agents can reduce ova survival and produce
severe chromosomal abnormalities that result in very
early embryonic death. This scenario is the classic
dominant lethal test. However, caffeine is unlikely to
increase the risk of birth defects by this mechanism
because even potent chemical mutagens and ionizing
radiation exposure to animals and humans before
conception do not cause a significant increase in the
incidence of genetic disease or birth defects in the live
offspring (Mulvihill et al., 1987; Ames and Gold, 1990;
Neel and Lewis, 1990; Nygaard et al., 1991a,b; Autrup,
1993; Brent, 1994, 1999, 2007; Byrne, 1999; Neel, 1999;
Boice et al., 2003; Winther et al., 2004).
CONCLUDING REMARKS
After reviewing the 2000 to 2010 scientific epidemiol-
ogy literature concerning the reproductive and develop-
mental toxicology risks of caffeine, we conclude that
major advances in the risk estimates have not been
made and the confounding phenomena continue to be
present in the present caffeine studies. An increase in
pharmacokinetic studies has not occurred. We still do
not know whether the increased risk estimates for
some developmental and reproductive effects at higher
exposures are due to caffeine or are due to other
confounding factors. It appears that we should
evaluate and continue to improve the animal studies to
determine whether we can answer the many unanswered
questions.
It may not be possible because of cost and invasiveness
for epidemiological investigators to initiate pharmacoki-
netic studies to determine the actual caffeine exposure in
the pregnant women exposed to caffeine that are being
studied for reproductive and developmental effects.
Further studies utilizing ‘‘cups’’ of tea, coffee, and colas
will add little more to the understanding of caffeine
‘‘toxicity’’ from the plethora of studies that have been
published.
The pharmacokinetics of caffeine and its metabolites
was reviewed if only to demonstrate the complexity
of evaluating caffeine’s toxic effects without knowing
the basic science of caffeine metabolism. Caffeine’s
main effect is on the central nervous system as a
stimulant that interacts with the adenosine receptor and
can also interact with adrenergic, cholinergic, GABA, or
serotonin receptors, the implications of which are
unknown.
1. In vivo animal caffeine studies should mimic human
exposures, which is oral administration.
2. Second, every epidemiology study that is initiated
should include recognition of the ‘‘pregnancy signal’’
as an important factor in determining the extent of
reproductive and developmental risks in the popula-
tion being studied.
3. Third, rarely has an investigator explained the MOA
of caffeine. How does caffeine produce growth
retardation, birth defects, SA, or premature births?
Caffeine is not mutagenic, oncogenic, or cytotoxic at
the usual human exposures. Agonism or antagonism
of the adenosine receptor is unlikely to be related to
developmental or reproductive toxic effects. It is
interesting that scores of investigators are interested
in the ‘‘toxic’’ effects of caffeine but not the mechan-
ism to explain the toxic effects.
4. Planning and analyzing epidemiological studies by
utilizing the principles of teratology would markedly
improve the caffeine epidemiology studies (Table 5).
Our conclusion is that the dietary exposures of caffeine
are not teratogenic or are directly responsible for an
increased risk of SA or fetal growth retardation. Studies
that involve very high exposures to caffeine are difficult
to evaluate because of the many confounding factors that
contribute to the risks that are not adequately evaluated;
however, the animal studies indicate that even the
highest human exposures in the epidemiological studies
are unlikely to have reproductive and developmental
effects (Table 10).
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